



**DRI HEALTHCARE TRUST**

MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE THREE MONTHS ENDED MARCH 31, 2026

# DRI HEALTHCARE TRUST

## MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2026

BASIS OF PRESENTATION .....	1
ADDITIONAL INFORMATION .....	1
FORWARD-LOOKING INFORMATION .....	1
REFERENCES AND DEFINED TERMS .....	2
USE OF NON-GAAP MEASURES .....	2
OVERVIEW OF THE TRUST .....	2
BUSINESS AND STRATEGY OVERVIEW .....	2
FINANCIAL REVIEW: RESULTS OF OPERATIONS .....	8
FINANCIAL REVIEW: NON-GAAP FINANCIAL MEASURES .....	15
FINANCIAL REVIEW: FINANCIAL POSITION .....	19
FINANCIAL REVIEW: CASH FLOWS .....	23
EQUITY .....	23
LIQUIDITY AND CAPITAL RESOURCES .....	26
OFF-BALANCE SHEET OBLIGATIONS AND COMMITMENTS .....	26
CONTINGENT LIABILITY .....	27
RELATED-PARTY TRANSACTIONS .....	27
CHANGES IN ACCOUNTING POLICIES .....	28
CRITICAL ACCOUNTING ESTIMATES .....	28
SUBSEQUENT EVENTS .....	28

# MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2026

## BASIS OF PRESENTATION

The following Management's Discussion and Analysis ("**MD&A**") is intended to help the reader understand the results of operations and financial condition of DRI Healthcare Trust (together with its consolidated subsidiaries, the "**Trust**"). This MD&A is provided as a supplement to, and should be read in conjunction with, the unaudited interim condensed consolidated financial statements of the Trust for the three months ended March 31, 2026 (the "**consolidated financial statements**"), as well as the audited annual consolidated financial statements of the Trust for the year ended December 31, 2025 (the "**2025 consolidated financial statements**"), including the accompanying notes to such financial statements. The consolidated financial statements of the Trust have been prepared in accordance with IFRS<sup>®</sup> Accounting Standards as issued by the International Accounting Standards Board ("**IASB**").

We present our financial statements in United States dollars ("**U.S. dollars**"). In this MD&A, all dollar amounts are expressed in U.S. dollars unless otherwise indicated. Accordingly, all references to "**US\$**", "**\$**" or "**dollars**" are to U.S. dollars, and all references to "**C\$**" are to Canadian dollars. Certain totals, subtotals and percentages throughout this MD&A may not reconcile due to rounding. Dollar amounts in the tables and elsewhere in this MD&A are presented in thousands of U.S. dollars except per unit data or unless otherwise noted.

The board of trustees of DRI Healthcare Trust has approved this disclosure.

This MD&A is prepared as of May 14, 2026.

## ADDITIONAL INFORMATION

Additional information relating to the Trust, including the Trust's annual and interim quarterly consolidated financial statements and management's discussion and analyses, annual information form and management information circular, are available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca). Solely for convenience, the products underlying our royalty assets may appear without the <sup>®</sup> or <sup>™</sup> symbol, but such references are not intended to indicate, in any way, that the owners of such trademarks will not assert their rights to such trademarks.

## FORWARD-LOOKING INFORMATION

This MD&A contains forward-looking information within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future financial outlook and anticipated events or results, and may include information regarding our financial position, business operations, business strategy, growth strategies, budgets, operations, financial results, taxes, distribution policy, plans and objectives.

In certain cases, forward-looking information includes statements that are predictive in nature, depend upon or refer to future events or conditions, and/or can be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions, and/or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, although not all forward-looking information contains these terms and phrases. Any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information, in particular, statements pertaining to the regulatory and clinical development of veligrotug and elegrobarb, the approval by court of the proposed settlement of the legal proceeding described herein, anticipated product commercialization, and the timing and amount of potential royalty payment and product sales. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. For instance, without limitation, the anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control. These risks and uncertainties also include, but are not limited to, the general economic and industry conditions, reliance on debt financing, our ability to leverage our competitive strength, and those described in greater detail under "Risk Factors" in the Trust's most recent annual information form, available under our profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information or interpret or regard forward-looking statements as guarantees of future outcomes. The forward-looking information contained in this MD&A has been prepared taking into consideration information available only to the date of this MD&A, or as of the date it is otherwise stated, and is subject to change after such date. However, we disclaim any intention, obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada.

## REFERENCES AND DEFINED TERMS

All references in this MD&A to the “Trust”, “we”, “us” and “our” are to DRI Healthcare Trust, together with its consolidated subsidiaries.

In this MD&A, the terms “royalties”, “royalty assets”, “royalty entitlements”, “royalty agreements” and “royalty streams” are used interchangeably to refer to either: (i) contractual arrangements that grant the buyer the right to receive royalties derived from the sale of pharmaceutical, biotechnology and other life science products pursuant to license agreements or other contractual arrangements (we refer to these as “**traditional**” royalty streams); or (ii) contractual arrangements that grant the buyer the right to receive a percentage of the top-line sales of pharmaceutical, biotechnology and other life science products directly from the marketer of the product (we refer to these as “**synthetic**” royalty streams). When we refer to having “**bought royalties**” on the sales of a particular product, or where we use similar expressions, we are generally referring to us having entered into the contractual arrangement that creates the traditional royalty or synthetic royalty stream in our favor. Unless the context otherwise requires, when we refer to terms such as “**our royalties**”, “**our portfolio**”, “**our royalty portfolio**”, “**our interests in products**” and similar terms, we are referring to our contractual interests in royalties and royalty streams that are held by our subsidiaries. When we refer to “**products**” and “**therapeutics**”, we are referring to the pharmaceutical, biotechnology or other life science products related to our royalties. When we refer to the “**pharmaceutical industry**”, we are referring generally to the pharmaceutical, biotechnology and other life science products industry.

## USE OF NON-GAAP MEASURES

This MD&A contains a number of financial performance measures and ratios that have been calculated using methodologies which are not in accordance with IFRS Accounting Standards (“**non-GAAP measures**”). These non-GAAP measures do not have a standardized meaning as prescribed by IFRS Accounting Standards and therefore are unlikely to be comparable to similar measures presented by other companies. We believe that providing these non-GAAP measures, in addition to our results under IFRS Accounting Standards, gives investors additional information for understanding the critical components of our financial performance. Accordingly, these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. These non-GAAP measures are used to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We also believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. We rely on these measures in the day-to-day management of our business, assessment of investment opportunities and assessment of our liquidity and borrowing needs.

Our uses, definition and calculation methodology, and the reconciliations of these non-GAAP measures to the most directly comparable measures calculated and presented in accordance with IFRS Accounting Standards, if available, for each of the measures, are presented under “Financial Review: Non-GAAP Financial Measures” on page 15 of this MD&A. The Trust has presented the following non-GAAP measures in this MD&A:

- Total Cash Receipts;
- Normalized Total Cash Receipts;
- Total Cash Royalty Receipts;
- Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“**Adjusted EBITDA**”);
- Adjusted EBITDA Margin; and
- Adjusted Cash Earnings per Unit.

## OVERVIEW OF THE TRUST

DRI Healthcare Trust was established as an unincorporated open-ended limited purpose trust under the laws of the Province of Ontario pursuant to a declaration of trust on October 21, 2020, as amended and restated on May 15, 2025. DRI Healthcare Trust is a “mutual fund trust” within the meaning of the *Income Tax Act* (Canada), but not a “mutual fund” within the meaning of applicable Canadian securities legislation. Effective July 1, 2025, DRI Healthcare Trust became a specified investment flow-through (“**SIFT**”) trust for the purposes of the *Income Tax Act* (Canada). DRI Healthcare Trust’s head and registered office is located at First Canadian Place, Suite 6200, 100 King Street West, Toronto, Ontario, M5X 1B8.

All references in this MD&A to “**former external manager**” are to Persis Capital Inc. (formerly DRI Capital Inc.). The former external manager provided management and other services to the Trust up to June 30, 2025, pursuant to the terms of a management agreement. On July 1, 2025, the Trust completed the internalization of its investment management function and terminated the management agreement between the Trust and the former external manager, as described on page 5 of this MD&A.

DRI Healthcare Trust’s Units (each a “**Unit**”, and collectively, “**Units**”) are listed on the Toronto Stock Exchange (“**TSX**”) in Canadian dollars under the symbol “**DHT.UN**” and in U.S. dollars under the symbol “**DHT.U**”.

## BUSINESS AND STRATEGY OVERVIEW

### Business Overview

We excel at sourcing, evaluating and completing transactions to purchase royalties paid on the sales of leading therapeutics. We do this by leveraging a track record of disciplined capital deployment, the skills and competencies of our highly skilled team, and our proprietary sourcing and diligence systems. We accelerate therapeutic innovation by providing capital to leading inventors working at top universities and research institutions, academic institutions, biotechnology companies and large pharmaceutical companies. We provide our holders of Units (“**Unitholders**”) with exposure to a broadly diversified portfolio of therapeutics that we expect will grow significantly in the medium and long term. We target royalties on products with the following characteristics:

- Medically necessary products that effectively treat chronic and critical illnesses;
- Products that benefit from strong intellectual property and/or regulatory protection; and

- Products that are marketed by leading biopharmaceutical companies.

As at March 31, 2026, our portfolio consisted of 28 royalty streams on 22 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (“**LSD**”) and immunology. Many of the royalty streams in our portfolio provide us with entitlements on products that we believe represent focus areas and important revenue sources for their respective marketers. The approved products underlying our royalty entitlements are marketed by leading global pharmaceutical and biotechnology companies, including Apellis Pharmaceuticals Inc. (“**Apellis**”), Biogen Inc. (“**Biogen**”), GSK plc (“**GSK**”), Galderma S.A. (“**Galderma**”), Johnson & Johnson Services, Inc (“**Johnson & Johnson**”), KalVista Pharmaceuticals, Inc. (“**KalVista**”), Menarini Group (“**Menarini**”), Novartis AG (“**Novartis**”), Rayner Surgical Inc. (“**Rayner Surgical**”), Regeneron Pharmaceuticals Inc. (“**Regeneron**”), Hoffman-La Roche AG (“**Roche**”), Sanofi S.A. (“**Sanofi**”), Swedish Orphan Biovitrum AB (“**Sobi**”) and Vertex Pharmaceuticals Inc (“**Vertex**”).

### Unique Growth Strategy

We are focused on providing our Unitholders with top-line exposure to a portfolio of attractive therapeutics by purchasing royalties on growing products that meet our investment criteria. We target an underserved niche that leverages the competitive advantages that the Trust has developed, including the specialized expertise of its team members and its access to data and information through its proprietary tools and know-how.

We believe the Trust has a number of advantages that are hard to replicate. One of these advantages is our proprietary database used to source transactions. This database tracks over 7,500 royalties on over 2,500 drugs worldwide. Another advantage is the deep relationships we have developed in our industry. Since our initial public offering through to March 31, 2026, we completed 16 royalty transactions related to 15 products and made additional investments by way of loans and private investment in public equity.

In order to generate sustainable annual growth in cash receipts, we initially targeted deployment of \$1.25 billion in transactions from the time of our initial public offering in February 2021 to the end of 2025. We have achieved this objective on a total commitment basis, including up to \$277 million in future contingent milestone payments related to our deals. Building on this track record, we have set an aspirational deployment range of \$800 million to \$1 billion in transactions from 2026 to the end of 2030. We expect to fund these royalty transactions predominantly using our cash on hand and through the prudent use of leverage.

### Our Assets

The Trust's assets currently comprise royalties on products that address a variety of therapeutic areas, such as oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, LSD and immunology. These products are marketed by leading global pharmaceutical and biotechnology companies, including Apellis, Biogen, GSK, Galderma, Johnson & Johnson, KalVista, Menarini, Novartis, Rayner Surgical, Regeneron, Roche, Sanofi, Sobi, and Vertex. In addition, the Trust holds a financial royalty asset that it acquired from the Casgevy transaction. The Casgevy royalty is classified as a financial royalty asset for accounting purposes due to the nature of the contractual cash flows. Our other royalties are classified as intangible royalty assets for accounting purposes.

We receive royalty payments based on the sales of pharmaceutical products in particular geographies. In general, when sales of these products increase, the payments we receive through our royalties also increase. The sales of products in turn can be affected by a number of factors, including regulatory approvals in new markets, the competitive landscape for the product and the approval of a product for new uses. We may also receive milestone royalty income based on the achievement of regulatory and/or sales performance thresholds in accordance with the terms of the underlying royalty agreements. Milestone royalty income is recognized in royalty income once the milestone event is achieved.

The table below provides an overview of our royalty assets as at March 31, 2026, and outlines expected royalty expirations based on our estimates of patent expiry dates in key geographies and the contractual agreements of each royalty stream. These estimates may be impacted by regulatory, commercial or other product developments. Variance from the anticipated performance of royalty-bearing sales may also affect these estimates as a result of caps or other structuring elements. See “Risk Factors” in our most recent annual information form.

Royalty Asset	Therapeutic Area	Primary Marketer(s)	FDA Approval Date	Expected Royalty Expiry <sup>(i), (ii)</sup>
Casgevy <sup>(iii)</sup>	Hematology	Vertex Pharmaceuticals	December 2023	Q1 2034
Ekterly	Immunology	KalVista	July 2025	Q1 2042
Empaveli/Syfovre <sup>(iv)</sup>	Hematology/Ophthalmology	Apellis, Sobi	May 2021	Q4 2033
Eylea I	Ophthalmology	Regeneron, Bayer, Santen	November 2011	Q1 2027
Eylea II	Ophthalmology	Regeneron, Bayer, Santen	November 2011	Q1 2027
Omidria	Ophthalmology	Rayner Surgical	May 2014	Q4 2031
Oracea	Dermatology	Galderma	May 2006	Q1 2028
Orserdu I	Oncology	Menarini	January 2023	Q1 2035
Orserdu II	Oncology	Menarini	January 2023	Q1 2035
Rydapt	Oncology	Novartis	April 2017	Q3 2028
Spinraza	Neurology	Biogen	December 2016	Q3 2031
Veligrotug/elegrobarb <sup>(v)</sup>	Ophthalmology	Viridian Therapeutics	Pending <sup>(v)</sup>	Q4 2042
Vonjo I	Hematology	Sobi	February 2022	Q2 2034
Vonjo II	Hematology	Sobi	February 2022	Q2 2034
Xenpozyme <sup>(vi)</sup>	Lysosomal Storage Disorder	Sanofi	August 2022	Q4 2036
Xolair	Immunology	Roche, Novartis	June 2003	Q2 2033
Zejula	Oncology	GSK	April 2022	Q2 2033
Zytiga	Oncology	Johnson & Johnson	September 2011 <sup>(vii)</sup>	Q2 2028

- (i) Represents the quarter during which the final royalty payment is expected and is based on our estimates of patent expiry dates in key geographies, loss of exclusivity and the contractual agreements of each royalty stream. These estimates may be impacted by regulatory, commercial or other product developments. Variance from the anticipated performance of royalty-bearing sales may also affect these estimates as a result of caps or other structuring.
- (ii) The anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control.
- (iii) Casgevy is classified as a financial royalty asset due to the nature of the contractual cash flows from the transaction, as described on page 9 of this MD&A.
- (iv) Empaveli/Syfovre includes two royalty streams on each product.
- (v) On December 22, 2025, Viridian announced that it submitted a BLA to the FDA for veligrotug in October 2025, which was accepted in December 2025. The BLA had been granted a Priority Review, with a PDUFA target action date of June 30, 2026. Viridian plans to submit a BLA for elegrobarb in Q1 2027.
- (vi) Xenpozyme includes two royalty streams.
- (vii) Represents the European Commission approval date.

## Key Developments Related to our Assets

### Elegrobarb

On March 30, 2026, Viridian Therapeutics, Inc. ("**Viridian**") announced positive topline results from the elegrobarb REVEAL-1 phase 3 clinical trial in patients with thyroid eye disease ("**TED**"). On May 5, 2026, Viridian announced positive topline results from REVEAL-2, the second pivotal phase 3 clinical trial of elegrobarb. Viridian anticipates submitting a Biologics License Application ("**BLA**") to the U.S. Food and Drug Administration ("**FDA**") for elegrobarb in Q1 2027.

### Veligrotug

On December 22, 2025, the FDA accepted the BLA for veligrotug for the treatment of TED. The BLA has been granted Priority Review, with a Prescription Drug User Fee Act ("**PDUFA**") target action date of June 30, 2026. If approved, royalty receipts from veligrotug from the Viridian Transaction, described on page 6 of this MD&A, are expected to be collected quarterly on a one-quarter lag, with the first royalty receipt being paid in the quarter immediately following the first commercial sale of veligrotug in the U.S.

### Ekterly

On July 7, 2025, the FDA approved Ekterly as the first and only oral on-demand therapy for treatment of hereditary angioedema attacks. The Trust began receiving royalties related to the Ekterly royalty entitlement in the fourth quarter of 2025.

### Omidria

Due to continued underperformance of the Omidria royalty asset in fiscal 2025, triggers for potential impairment were identified. As such, we were required to determine the recoverable amounts to assess if the Omidria intangible royalty asset is impaired. We calculated the recoverable amount for Omidria as at December 31, 2025 using a discounted cash flow model based on revised forecasted cash flows adjusted for the impact of the current market environment. The key assumptions and sources of estimation uncertainty are related to the discount rate and future cash flows, including future sales of Omidria and key competitors. Based on our analysis, the net book value of Omidria exceeded its recoverable amount, and the Trust recorded an impairment of \$9,674 for the year ended December 31, 2025. As a result of recognizing the impairment, the net book value of the Omidria intangible royalty asset as at December 31, 2025 was \$147,008, which represents the recoverable amount.

### Vonjo I and Vonjo II

During fiscal 2025, competitive pressures continued to have a greater impact than initially anticipated and combined with recent unfavorable net pricing changes impacting sales of Vonjo, these conditions represented indicators of potential impairment of the Trust's Vonjo I and Vonjo II intangible royalty assets. As such, we were required to determine the recoverable amounts to assess if the Vonjo assets are impaired. We calculated the recoverable amounts for Vonjo I and Vonjo II as at September 30, 2025 using a discounted cash flow model based on revised forecasted cash flows adjusted for the greater impact of competition, changes in net pricing and current market uptake of Vonjo. The key assumptions and sources of estimation uncertainty are related to the discount rate and future cash flows, including future sales of Vonjo and key competitors. Based on our analysis, the net book value of Vonjo II exceeded its recoverable amount, and the Trust recorded an impairment of \$13,691 for Vonjo II as at September 30, 2025. Based on the updated forecast, the net book value of Vonjo I was lower than the recoverable amount and no impairment was recognized on this asset. As a result of recognizing the impairment, the net book value of the Vonjo II intangible royalty asset as at September 30, 2025 was \$39,015, which represents the recoverable amount.

Despite the Vonjo I and Vonjo II intangible royalty assets both relating to the same product, due to differences in the timing of the transactions, terms of the agreements and calculation of royalty entitlement, only the Vonjo II intangible royalty asset required impairment as a result of the revised cash flow forecast.

### Orserdu

During the year ended December 31, 2025, Orserdu sales exceeded certain sales performance thresholds that triggered milestone royalty income for Orserdu I of \$5,000, which was recognized in royalty income in the fourth quarter of 2025. The milestone royalty income was received in the first quarter of 2026.

### Other Key Events

#### *Internalization*

On July 1, 2025, the Trust completed the previously announced transaction to internalize its investment management function. In connection with the internalization, the Trust and the former external manager entered into a certain termination agreement pursuant to which (i) the management agreement with the former external manager was terminated, effective June 30, 2025; and (ii) the former external manager agreed to indemnify the Trust and its affiliates in respect of, among other things, damages, if any, related to an internal investigation into irregularities related to expenses charged to the Trust by the former external manager in 2024. To extinguish the former external manager's management agreement, along with all management and performance fee obligations, the Trust paid a termination fee of \$48,000. The termination of the former external manager results in the elimination of management and performance fees on a go forward basis.

In addition, in connection with the internalization, the Trust acquired certain relevant assets of the former external manager for a purchase price of \$1,000. As a result of the transaction contemplated by a certain asset purchase agreement entered into between the Trust and the former external manager, the employees of the former external manager transitioned to a subsidiary of the Trust.

#### *Normal Course Issuer Bid ("NCIB")*

On May 9, 2025, we were granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,148,536 Units of the Trust for cancellation between May 20, 2025 and May 19, 2026 ("**May 2025 NCIB**"). In connection with the May 2025 NCIB, the Trust established an automated unit purchase plan ("**AUPP**") whereby Units of the Trust may be repurchased, between May 20, 2025 and May 19, 2026, at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

During the three months ended March 31, 2026, the Trust acquired and canceled 75,938 Units at an average price of \$11.31, totaling \$859. As at March 31, 2026, in aggregate, we have acquired and canceled 4,688,696 Units at an average price per Unit of \$7.15, totaling \$33,517, under all current and previous normal course issuer bid plans ("**NCIB Plans**"). Our NCIB Plans are discussed further on page 24 of this MD&A.

Subsequent to March 31, 2026, the Trust was granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,060,594 Units of the Trust for cancellation between May 20, 2026 and May 19, 2027. From April 1, 2026 to May 14, 2026, we acquired an additional 60,052 Units under the May 2025 NCIB plan at an average price of \$11.65, totaling \$700 under the AUPP.

#### *Credit Facility*

On May 12, 2025, we received lender consent for the internalization of the investment management function. We also further revised our credit agreement (as defined herein) to reallocate \$25,000 of the acquisition credit facility to the working capital credit facility, increasing it to \$50,000. The credit available for investment remains unchanged as the working capital credit facility can be used for investment purposes. Furthermore, the interest rate on the amended credit agreement was revised to the Secured Overnight Financing Rate ("**SOFR**") plus (i) a margin which may vary from 1.75% to 2.50% based on the Trust's leverage ratio; and (ii) a margin of 0.10%. All other material terms of the amended credit agreement remain unchanged. Our credit facility is discussed in further detail on page 20 of this MD&A.

On October 3, 2025, we amended our credit agreement to, among other things, convert and merge the term credit facility into the acquisition credit facility. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250. This increased the total credit available under the acquisition credit facility to \$570,000. The Trust also extended the maturity date of the amended credit agreement by two years to October 3, 2029, which may be extended by one-year increments subject to lender approval. Certain other terms were also adjusted to provide the Trust with greater flexibility. All other material terms of the amended credit agreement remain unchanged.

On February 24, 2026, the Trust further amended its credit agreement to permit the issuance of up to \$250,000 of the senior secured notes (the "**Senior Notes**") on a private placement basis. The amendments also included having the Senior Notes rank *pari passu* with the credit agreement and to be secured by the same collateral.

#### *Senior Notes*

On March 24, 2026, the Trust completed a private placement of \$250,000 Senior Notes, consisting of two tranches with staggered maturities. The Senior Notes are discussed in further detail on page 22 of this MD&A.

#### *Interest Rate Swap*

On June 10, 2025, to reflect changes resulting from amendments to the credit agreement, we extended the maturity on our original interest rate swap to November 1, 2027, and entered into a second interest rate swap agreement with equivalent terms for an additional notional amount of \$50,000. Under the agreements, we pay a fixed rate and in exchange receive a SOFR interest rate, offsetting the floating component on a portion of the credit facility.

On December 1, 2025, as a result of the October 3, 2025 amendment to the credit agreement, the Trust further modified its interest rate swap. The maturity date was extended to September 28, 2029. The second aforementioned interest rate swap was combined with the original interest rate swap into a single \$150,000 notional interest rate swap. The interest rate swap is discussed in further detail on page 13 of this MD&A.

#### *Preferred Securities*

On June 18, 2025, the Trust purchased and canceled \$10,000 in face value of the Series C Preferred Securities ("**2024 Preferred Securities**") for \$9,500. The Trust paid outstanding accrued interest on the \$10,000 face value up to and including June 18, 2025, the date of the transaction.

On February 10, 2026, the Trust purchased and canceled \$9,924 in face value of the 2024 Preferred Securities for \$9,825. The Trust paid outstanding accrued interest on the \$9,924 face value up to February 10, 2026, the date of the transaction.

#### *Convertible Debentures*

On March 20, 2026, the Trust issued C\$108,723 aggregate principal amount of convertible unsecured subordinated debentures (the "**debentures**") to the holders of the 2024 Preferred Securities. The purchase price for the debentures was exclusively satisfied through the exchange of \$79,698 in principal amount of the outstanding 2024 Preferred Securities. No cash consideration was paid by the holders of the 2024 Preferred Securities. Upon closing, an aggregate principal amount of \$35,580 of the 2024 Preferred Securities remain issued and outstanding. The 2024 Preferred Securities and debentures are discussed in further detail on page 21 of this MD&A.

#### *Distributions*

During the three months ended March 31, 2026, the board of trustees of the Trust declared a quarterly cash distribution of 0.11 per Unit totaling \$6,052 to Unitholders of record as at March 31, 2026, which was paid on April 20, 2026. Additionally, on January 20, 2026, we paid \$5,507 of cash distributions declared in 2025.

We pay quarterly distributions in accordance with our distribution policy. Distributions are discussed in further detail in note 7 to the consolidated financial statements.

### **Recent Transactions Completed**

#### *Orserdu II Milestone Payment*

On January 24, 2025, we paid \$10,000 to fund the Orserdu II milestone obligation as a result of certain pre-specified events outlined in the purchase agreement having been met.

#### *Ekterly Optional Payment*

On July 7, 2025, KalVista elected to receive the one-time optional payment of \$22,000 as part of the Ekterly transaction completed in 2024. As a result of the payment, the Trust's royalty entitlement on net sales up to and including \$500,000 increased from 5.0% to 6.0% and the potential one-time sales-based milestone payment to KalVista increased from \$50,000 to \$57,000. The Trust funded the payment on July 9, 2025.

#### *Veligrotug and elegrobart Transaction*

On October 17, 2025, the Trust acquired a royalty interest in the U.S. net sales of veligrotug and elegrobart from Viridian for an aggregate purchase price of up to \$300,000, including a \$55,000 upfront payment and up to \$245,000 subject to the achievement of certain milestones. As of March 31, 2026, certain pre-specified clinical milestone events defined under the purchase agreement have not been achieved, which reduces the Trust's maximum potential milestone obligation to \$205,000, of which \$75,000 is related to a near-term regulatory milestone payment. The transaction entitles the Trust to tiered royalties on annual U.S. net sales of veligrotug and elegrobart, consisting of 7.50% on annual U.S. net sales up to and including \$600,000, 0.80% on annual U.S. net sales above \$600,000 and up to and including \$900,000, and 0.25% on annual U.S. net sales above \$900,000 and up to and including \$2,000,000. Royalty receipts will be collected quarterly on a one-quarter lag, with the first royalty receipt being paid in the quarter immediately following the first commercial sale of veligrotug in the U.S. Transaction costs of \$1,990 were capitalized as part of the royalty transaction.

Veligrotug has shown clinically meaningful improvements across both active and chronic TED. Veligrotug has met all primary and secondary endpoints across proptosis, Clinical Activity Score and diplopia in each of its two pivotal phase 3 clinical trials, THRIVE-1 and THRIVE-2 for patients with active and chronic TED, respectively. Viridian submitted a BLA to the FDA for veligrotug in October 2025, which was accepted in December 2025. The BLA has been granted a Priority Review, with a PDUFA target action date of June 30, 2026. If approved, veligrotug will be only the second approved biologic treatment for TED, with the potential to improve patients' quality of life with fewer doses and less time required for a full treatment course.

Viridian is also advancing elegrobart, a potential best-in-class subcutaneous therapy for the treatment of TED via a program including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, in patients with active and chronic TED, respectively. During the first half of 2026, Viridian announced positive topline results that REVEAL-1 and REVEAL-2 both met the primary endpoint of the clinical trials with a highly statistically significant treatment effect. Subject to positive outcomes and subsequent regulatory review, Viridian plans to submit a BLA in the first quarter of 2027. If approved, elegrobart is expected to provide additional convenience benefits with a low-volume autoinjector designed for self-administration planned for commercial launch.

*Summary of Recent Transactions Completed*

The following is a summary of the recent transactions completed:

	Ekterly Optional Payment	Veligrotug and elegrobart Transaction	Total
Assets			
Intangible royalty assets	\$ 22,000	\$ 55,000	\$ 77,000
Net acquired assets	\$ 22,000	\$ 55,000	\$ 77,000

## FINANCIAL REVIEW: RESULTS OF OPERATIONS

During the three months ended March 31, 2026, the Trust recorded a net loss of \$984, composed of total income of \$50,561, total expenses of \$42,154, a net loss on debt refinancing of \$9,794 and an income tax recovery of \$403. The Trust also had a net unrealized gain on derivative instruments of \$1,443 which resulted in comprehensive earnings of \$459.

During the three months ended March 31, 2025, the Trust incurred a net loss of \$1,752, composed of total income of \$44,028 and total expenses of \$45,780. The Trust also incurred a net unrealized loss on derivative instruments of \$80, which resulted in a comprehensive loss of \$1,832.

The following table presents the components of net earnings (loss) and comprehensive earnings (loss) and is followed by a discussion of the nature of significant sources of income and categories of expenses.

	Three months ended	
	March 31, 2026	March 31, 2025
<b>Income</b>		
Royalty income	\$ 46,599	\$ 39,634
Change in fair value of financial royalty assets	1,654	2,561
Net gain (loss) on marketable securities	168	1,535
Net unrealized gain on derivative instruments	253	—
Net unrealized gain on foreign exchange remeasurement	1,664	—
Other interest income	223	298
<b>Total income</b>	<b>50,561</b>	<b>44,028</b>
<b>Expenses</b>		
Amortization of intangible royalty assets	24,948	24,745
Management fees	—	4,076
Performance fees	—	533
Interest expense	10,405	9,607
Deal investigation and research expenses	726	1,057
Compensation expense <sup>(i)</sup>	2,891	369
Unit-based compensation	668	460
General and administrative expenses <sup>(i)</sup>	550	101
Other operating expenses <sup>(i)</sup>	1,966	4,832
<b>Total expenses</b>	<b>42,154</b>	<b>45,780</b>
<b>Gain (loss) on debt refinancing</b>	<b>(9,794)</b>	<b>—</b>
<b>Net earnings (loss) before tax</b>	<b>\$ (1,387)</b>	<b>\$ (1,752)</b>
<b>Income tax recovery (expense)</b>	<b>403</b>	<b>—</b>
<b>Net earnings (loss)</b>	<b>\$ (984)</b>	<b>\$ (1,752)</b>
<b>Other comprehensive earnings (loss)</b>		
Net unrealized gain (loss) on derivative instruments	1,443	(80)
<b>Comprehensive earnings (loss)</b>	<b>\$ 459</b>	<b>\$ (1,832)</b>

(i) Prior period figures have been adjusted to conform with the current period's classification.

### Royalty income

Royalty income is composed of income from our intangible royalty assets, which represent the contractual right to receive, directly or indirectly, a royalty payment, milestone royalty payment, license fee or any other form of compensation or benefit arising from or contingent upon the use of any patent, trade secret or any other form of intellectual property or other right relating to pharmaceutical drugs, devices and/or delivery technologies. The Trust typically does not own the licensed intellectual property; rather, it earns income based on rights to a royalty stream generally tied to the related underlying patent, calculated as a percentage of sales revenue generated by a third party at the time the sales occur. Royalty income is recorded on an accrual basis when earned in accordance with our contractual rights. Management is required to make estimates of royalty income earned for which a report or actual cash royalty receipts have not been received from our counterparty. Actual royalty receipts are reported and paid by our counterparties typically one or more quarters after they are earned. Actual milestone royalty receipts are received after the milestone condition has been met and they are paid in accordance with the terms of the agreement with the counterparty.

The following table presents the Trust's royalty income by intangible royalty asset for the three months ended March 31, 2026 and 2025.

	Three months ended March 31, 2026	Three months ended March 31, 2025	\$ Change	% Change
<b>Intangible Royalty Assets</b>				
Ekterly	\$ 1,768	\$ —	\$ 1,768	n/a
Empaveli/Syfovre <sup>(i)</sup>	3,301	2,755	546	20 %
Eylea I	901	1,195	(294)	(25)%
Eylea II	190	259	(69)	(27)%
Omidria	7,343	6,682	661	10 %
Oracea	924	1,277	(353)	(28)%
Orserdu I	8,280	5,724	2,556	45 %
Orserdu II	8,280	5,724	2,556	45 %
Rydapt	633	1,279	(646)	(51)%
Spinraza	3,773	3,620	153	4 %
Vonjo I	3,037	4,106	(1,069)	(26)%
Vonjo II	633	855	(222)	(26)%
Xenpozyme <sup>(ii)</sup>	1,399	1,188	211	18 %
Xolair	4,235	2,856	1,379	48 %
Zejula	1,314	1,115	199	18 %
Zytiga	37	295	(258)	(87)%
Other Products <sup>(iii)</sup>	551	704	(153)	(22)%
<b>Total Royalty Income</b>	<b>\$ 46,599</b>	<b>\$ 39,634</b>	<b>\$ 6,965</b>	<b>18 %</b>

(i) Empaveli/Syfovre includes two royalty streams on each product.

(ii) Xenpozyme includes two royalty streams.

(iii) Other Products includes intangible royalty assets which are not individually material, as well as intangible royalty assets which are fully amortized or, where applicable, the entitlements to which have substantially expired. Natpara current period and comparative results have been moved to Other Products starting in Q1 2026.

The Trust records royalty income from intangible royalty assets from the date on which the Trust obtains control of those assets, which is typically the date on which the agreement creating the intangible royalty assets is entered into.

Royalty income for the three months ended March 31, 2026 was \$46,599, which increased by \$6,965 or 18% compared to the same period in 2025. The increase in royalty income is primarily driven by Orserdu due to the growth in its sales. Ekterly also contributed an additional \$1,768 in royalty income in the quarter as the Trust began receiving royalty income for Ekterly at the start of Q3 2025. Additionally, the continued strong performance of Xolair sales due to the successful launch of its food allergy indication also contributed to the growth in royalty income.

Partially offsetting these increases were lower sales for Vonjo due to ongoing competitive pressures, lower sales for Rydapt as prior year income included a one-time adjustment in sales and decline in sales for Oracea due to competition from generic products.

#### Change in fair value of financial royalty assets

In 2024, the Trust acquired a financial royalty asset through the Casgevy transaction. As a result of the nature of the contractual cash flows from the transaction, which primarily consist of fixed and determinable amounts not dependent on the underlying pharmaceutical product, the Trust's entitlement to the royalty license payment streams is classified as a financial royalty asset and changes in fair value are recognized in net earnings.

During the three months ended March 31, 2026, the carrying amount of the financial royalty asset decreased to \$53,930 from \$57,276 at December 31, 2025. The decrease is attributed to cash receipts of \$5,000 from the Casgevy asset, partially offset by a net change in fair value of \$1,654 during the three months ended March 31, 2026. The net change in fair value is composed of accretion towards future value due to the passage of time of \$1,868 and a decrease in fair value of \$214 due to movements in the risk-free rate.

During the three months ended March 31, 2025, the net change in fair value of financial royalty assets was \$2,561, and was composed of accretion towards future value due to the passage of time of \$1,926 and an increase in fair value of \$635 due to the movements in the risk-free rate.

#### Net gain (loss) on marketable securities

As part of the Ekterly transaction completed in 2024, the Trust purchased 500,000 shares of KalVista common stock in a private transaction for \$10 per share for a total purchase price of \$5,000. Changes in the fair value of marketable securities are recognized in net earnings (loss). During the three months ended March 31, 2026, the Trust sold 205,000 shares for an average price of \$16.97, which resulted in the Trust recognizing a realized gain of \$1,429. Prior to the sale during the quarter, the Trust recorded an unrealized loss of \$1,261 related to the change in fair value of the marketable securities, which results in a net gain of \$168 recognized for the quarter.

During the three months ended March 31, 2025, the Trust did not sell any shares of the marketable securities and did not record a realized gain. The Trust recorded an unrealized gain of \$1,535 related to the change in fair value of the marketable securities.

### Amortization of intangible royalty assets

Intangible royalty assets are amortized over the estimated economic useful life of the assets, as described in note 3(c) to the Trust's 2025 consolidated financial statements. The Trust amortizes its intangible royalty assets beginning on the date on which the Trust begins receiving economic benefit from the royalty asset. During the three months ended March 31, 2026, the Trust recorded amortization of intangible royalty assets of \$24,948 (2025 – \$24,745).

The increase in amortization expense compared to the prior period is primarily due to the commencement of amortization of Ekterly, following the onset of sales in Q3 2025. Partially offsetting the increase were the impairments recorded on Omidria and Vonjo II in the prior year, which reduced the amortizable base of those intangible royalty assets and thus the amortization for these royalty assets.

### Management fees

During the three months ended March 31, 2026, the Trust did not incur or pay for management fees due to the termination of the former external management agreement effective July 1, 2025, as described on page 5 of this MD&A. During the three months ended March 31, 2025 the Trust recorded management fees of \$4,076 related to services provided by the former external manager, prior to the internalization transaction.

### Performance fees

During the three months ended March 31, 2026, the Trust did not incur or pay for performance fees due to the termination of the former external management agreement effective July 1, 2025, as described on page 5 of this MD&A. During the three months ended March 31, 2025, the Trust recorded performance fees of \$533 as the conditions for performance fee payments were met primarily due to the cash receipt on Casgev.

### Interest expense

The Trust's interest expense relates to interest incurred on the Trust's long-term debt. Interest expense for the three months ended March 31, 2026 and 2025 is presented below. The increase in interest expense is primarily attributable to the additional interest incurred on the debentures and Senior Notes, which were both newly issued during the three months ended March 31, 2026.

Additionally, the Trust entered into interest rate swaps to exchange floating for fixed interest rates on a notional amount of \$150,000, as further described on page 21 of this MD&A. The Trust uses the interest rate swap as a derivative financial instrument designated as a cash flow hedge to manage interest rate risk related to its credit facility. During the three months ended March 31, 2026, the Trust recorded an increase in interest due to the interest rate swaps of \$307 (2025 – \$75). Partially offsetting the increase was the reduction in interest charged on the 2024 Preferred Securities also due to decrease in its outstanding principal amount.

		Three months ended March 31, 2026		Three months ended March 31, 2025
Interest on credit facility net borrowings	\$	5,470	\$	5,248
Standby fees		285		299
Amortization of deferred transaction costs		744		398
Increase (reduction) in interest expense from interest rate swap		307		75
<b>Total interest expense on credit facility</b>	<b>\$</b>	<b>6,806</b>	<b>\$</b>	<b>6,020</b>
Interest on preferred securities	\$	2,035	\$	2,500
Accretion of par value		872		951
Amortization of deferred transaction costs		181		136
<b>Total interest expense on preferred securities</b>	<b>\$</b>	<b>3,088</b>	<b>\$</b>	<b>3,587</b>
Interest on debentures	\$	147	\$	—
Accretion of par value		66		—
Amortization of deferred transaction costs		23		—
<b>Total interest expense on debentures</b>	<b>\$</b>	<b>236</b>	<b>\$</b>	<b>—</b>
Interest on Senior Notes	\$	268	\$	—
Amortization of deferred transaction costs		7		—
<b>Total interest expense on senior notes</b>	<b>\$</b>	<b>275</b>	<b>\$</b>	<b>—</b>
<b>Total interest expense</b>	<b>\$</b>	<b>10,405</b>	<b>\$</b>	<b>9,607</b>

### Deal investigation and research expenses

Deal investigation and research expenses include the ongoing costs associated with the Trust's research and due diligence activities and other expenses necessary for the assessment of potential asset acquisition opportunities, including consulting, legal, research data and data subscription expenses.

For the three months ended March 31, 2026, the Trust recorded deal investigation and research expenses of \$726 (2025 – \$1,057). The year-over-year decrease is primarily due to lower legal costs in the current period compared to the first quarter of 2025.

### Compensation expense

During the three months ended March 31, 2026, the Trust recognized compensation expense of \$2,891 compared to \$369 recorded in the same period in 2025. The increase year-over-year is primarily due to the compensation of all employees now being reclassified and directly recorded in the compensation expense line post internalization, partially offset by the favorable impact of related internalization synergies. As noted previously, internalization of the management function by the Trust was completed on July 1, 2025, as described on page 5 of this MD&A, resulted in employees of the former external manager becoming employees of the Trust, with the compensation of these employees reflected in the Trust's results from July 1, 2025 onwards as compensation expense. Prior to internalization, compensation of the manager employees had been incorporated in the management fee paid to the former external manager.

During the three months ended March 31, 2025, compensation expense only included compensation paid to the Trust's Chief Executive Officer and the Chief Financial Officer.

### Unit-based compensation

The Trust provides unit-based compensation under its Omnibus Equity Incentive Plan, as described in note 3(o) to the Trust's 2025 consolidated financial statements.

For the three months ended March 31, 2026, the unit-based compensation expense was \$668 compared to \$460 recorded during the same period in 2025, and was composed of Restricted Unit ("RU") grants, net of RUs vestings and any RU forfeitures during the period. As at March 31, 2026, the unit-based compensation liability was \$2,063 (December 31, 2025 – \$1,903), composed of a current portion of \$1,739 and a long-term portion of \$324 (December 31, 2025 – \$1,704 and \$199, respectively) related to the outstanding awards.

The following table provides the details of RUs up to March 31, 2026.

	Restricted Units
<b>Balance – January 1, 2025</b>	<b>437,371 Units</b>
Distribution equivalent Units granted <sup>(i)</sup>	5,291 Units
Vesting of Restricted Units	(14,109) Units
<b>Balance – March 31, 2025</b>	<b>428,553 Units</b>
Restricted Units granted:	
Granted on July 01, 2025 <sup>(ii)</sup>	99,254 Units
Granted on July 01, 2025 <sup>(iii)</sup>	99,254 Units
Granted on September 04, 2025 <sup>(iv)</sup>	7,580 Units
Granted on September 04, 2025 <sup>(v)</sup>	13,125 Units
Granted on October 15, 2025 <sup>(iii)</sup>	17,158 Units
Granted on November 10, 2025 <sup>(vi)</sup>	8,917 Units
Distribution equivalent Units granted <sup>(i)</sup>	7,439 Units
Vesting of Restricted Units	(375,821) Units
Forfeiture of Restricted Units	(4,243) Units
<b>Balance – December 31, 2025</b>	<b>301,216 Units</b>
Restricted Units granted:	
Granted on March 31, 2026 <sup>(vii)</sup>	16,162 Units
Distribution equivalent Units granted <sup>(i)</sup>	2,470 Units
Vesting of Restricted Units	(42,217) Units
<b>Balance – March 31, 2026</b>	<b>277,631 Units</b>

(i) All RUs are credited with distribution equivalents in the form of additional RUs on each distribution payment date in respect of which normal distributions are paid on the Trust's Units. Such distribution equivalents are subject to the same vesting conditions as the instruments to which they relate.

(ii) Vesting equally on a quarterly basis beginning October 1, 2025 until July 1, 2026.

(iii) Vested equally over three years on each anniversary date.

(iv) Vesting equally on September 10, 2025, September 10, 2026 and September 10, 2027.

(v) Vesting equally on April 1, 2026, April 1, 2027 and April 1, 2028.

(vi) Vesting equally on a quarterly basis beginning November 13, 2025 until August 13, 2026.

(vii) Vesting on March 31, 2029.

No Options or Performance Units ("PUs") were granted as at March 31, 2026 and December 31, 2025. Certain members of the board of trustees of the Trust elected to be compensated fully or partially in Deferred Units ("DUs"), as described in the other operating expenses section below.

### General and administrative expenses

General and administrative expenses include overhead costs incurred in the management of the business, such as depreciation of fixed assets, amortization of other intangibles, insurance, premises and office expenses, among others.

Year-over-year, general and administrative expenses increased to \$550 compared to \$101. The increase is driven primarily by the reclassification of these expenses post internalization as these general and administrative expenses were previously incorporated in the management fee paid to the former external manager but are now being directly recorded in the general and administrative line. The increase is partially offset by synergies realized driven by internalization efficiencies. General and administrative expenses for the three months ended March 31, 2026 included expenses of \$88 related to the depreciation of fixed assets and other intangible assets, \$134 related to premises and office expenses, including insurance, and \$233 in general and administrative expenses related to the manager entities, net of synergies realized.

### Other operating expenses

Other operating expenses include fees paid to the board of trustees of the Trust and other ongoing operating expenses, including consulting, legal and audit fees required to operate our business.

During the three months ended March 31, 2026, the Trust recorded total other operating expenses of \$1,966 compared to \$4,832 recorded in the same period during 2025. The decrease year-over-year is described in more detail below.

A summary of the Trust's other operating expenses by nature is presented below.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Board of trustees fees	\$ 437	\$ 254
Professional fees	992	4,111
Other expenses <sup>(i)</sup>	537	467
<b>Total other operating expenses</b>	<b>\$ 1,966</b>	<b>\$ 4,832</b>

(i) Prior period figures have been adjusted to conform with the current period's classification.

### Board of trustees fees

Certain members of the board of trustees of the Trust have elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan. The DUs granted pursuant to the election vest immediately and are settled in accordance with the established terms of the award agreement, but not earlier than the resignation or termination of the respective trustee from the board of trustees of the Trust. All DUs are credited with distribution equivalents in the form of additional DUs on each distribution payment date in respect of which normal distributions are paid on the Trust's Units. Such distribution equivalents are subject to the same vesting conditions as the instruments to which they relate. DUs are initially recognized at fair value and are subsequently remeasured at fair value on each reporting date, as described in note 3(o) to the Trust's 2025 consolidated financial statements.

During the three months ended March 31, 2026, the Trust recorded board of trustees fees of \$437, which increased \$183 compared to the same period in 2025. The increase in board compensation expense was primarily driven by additional DUs granted to the Board of Trustees due to an increase in Trustee elections for compensation in DUs and an increase in the fair value of the DUs. Partially offsetting the increase was lower cash compensation paid to the Board of Trustees, as the three months ended March 31, 2025 included a special committee fee of \$120 related to enhancing governance processes in connection with the internalization transaction, described on page 5 of this MD&A.

Included in Board of trustees fees for the three months ended March 31, 2026 are costs related to the issuance of DUs and the related distribution equivalents of \$366 (2025 – \$104). During the three months ended March 31, 2026, the Trust granted 13,979 DUs (2025 – 16,328) in lieu of cash compensation to trustees and 2,036 distribution equivalent Units (2025 – 2,444) in relation to the quarterly distributions. The total fair value of the DUs vested but not settled was \$2,803 as at March 31, 2026 (December 31, 2025 – \$2,437) and was included in other current liabilities.

### Professional fees

For the three months ended March 31, 2026, the Trust recorded total professional fees of \$992 related to professional services including audit, legal, tax, valuation and consulting. Included in professional fees during the three months ended March 31, 2026 is \$344 related to the issuance of the conversion option on the Trust's debentures, as described on page 22 of this MD&A. This is a one-time cost not expected to recur.

During the three months ended March 31, 2025, the Trust recorded total professional fees of \$4,111, including \$1,588 incurred to enhance governance functions following the investigation into irregular expenses charged to the Trust, as described on page 27 of this MD&A, and \$2,199 in legal expenses related to entity management in connection with the internalization transaction, as described on page 5 of this MD&A. These incremental governance and entity management costs associated with the investigation and internalization did not recur in 2026.

### Other expenses

Other expenses for the three months ended March 31, 2026 were \$537 (2025 – \$467) and included \$250 in donations (2025 – \$263), primarily related to the pledge agreement with the Mayo Clinic, as described on page 26 of this MD&A.

### Gain (loss) on debt refinancing

For the three months ended March 31, 2026, the Trust recognized a net loss on debt refinancing of \$9,794 (2025 – nil) related to its 2024 Preferred Securities, as described on page 21 of this MD&A. In February 2026, the Trust recognized a loss of \$1,162 related to the partial purchase and cancellation of the 2024 Preferred Securities. In March 2026, the Trust recognized a loss of \$7,380 resulting from extinguishing a portion of the 2024 Preferred Securities in exchange for issuing new debentures, as described on page 21 of this MD&A. Unamortized deferred transaction costs of \$1,252 related to the portion of the 2024 Preferred Securities exchanged are also recognized as a loss on debt refinancing.

### Income tax expense

Related to the updated corporate structure of the Trust as a result of the internalization transaction as described on page 5 of this MD&A, certain subsidiaries of the Trust are subject to income taxes starting July 1, 2025. The Trust remains non-taxable, and the reported income tax expense reflects taxes payable by certain Trust subsidiaries. During the three months ended March 31, 2026, the Trust recorded an income tax recovery of \$403 (2025 – nil).

### Net unrealized gain (loss) on derivative instruments

#### Interest rate swap

The Trust uses interest rate swaps as a derivative financial instrument designated as a cash flow hedge to manage interest rate risk related to its credit facility, as described on page 21 of this MD&A. On August 31, 2023, the Trust entered into an interest rate swap agreement to fix the interest rate on a notional amount of \$100,000 of the credit facility. On June 10, 2025, to reflect changes resulting from amendments to the amended credit agreement, as described on page 20 of this MD&A, the Trust extended the maturity on its original interest rate swap to November 1, 2027. On June 10, 2025, the Trust also entered into a second interest rate swap with equivalent terms for an additional notional amount of \$50,000 to further manage interest rate risk on the credit facility. On December 1, 2025, as a result of the October 3, 2025 amendment to the credit agreement, the Trust further modified its interest rate swap. The maturity date was extended to September 28, 2029. The second aforementioned interest swap was combined with the original interest rate swap into a single \$150,000 notional interest rate swap. The hedge accounting for the amended and second interest rate swaps from June 2025 was discontinued and the new interest rate swap was designated as a cash flow hedge. The Trust does not hold or use any derivative financial instruments for speculative trading purposes. Under the agreements, the Trust pays a fixed rate and in exchange receives a SOFR interest rate, offsetting the floating component on a portion of the credit facility.

During the three months ended March 31, 2026, the Trust recorded \$150 (2025 – nil) in net unrealized gain on derivative instruments which represents the ineffective portion of the hedge and recognized a net gain in unrealized fair value of \$1,443 (2025 – net loss of \$80) into other comprehensive income which represents the effective portion of the hedge.

The details of the interest rate swap are as follows.

Derivative Instruments	Maturity Date	Notional Value	Fair Value as at March 31, 2026	Fair Value as at December 31, 2025
Interest rate swap	September 28, 2029	\$ 150,000	\$(163)	\$(1,486)

#### Conversion Option

In connection with the issuance of debentures described on page 22 of this MD&A, the Trust recognized an embedded derivative liability for the conversion option of the debentures. During the three months ended March 31, 2026, the Trust recognized a net gain of \$103 (2025 – nil) in profit or loss related to the fair value change of the conversion option derivative instrument.

### Net unrealized (gain) loss on foreign exchange remeasurement

The Trust remeasures its financial instruments denominated in foreign currencies using the period end spot rate. For the three months ended March 31, 2026, the Trust recorded a net gain of \$1,664 related to the remeasurement of its debentures (2025 – nil).

### Weighted average number of Units

For the three months ended March 31, 2026, the Trust generated basic and diluted net earnings (loss) per Unit of \$(0.02) (2025 – \$(0.03)). The weighted average number of Units outstanding for the purpose of calculating net earnings (loss) per Unit was as follows.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Basic	55,039,344 Units	56,307,817 Units
Diluted	55,039,344 Units	56,307,817 Units

**Summary of quarterly results**

The following table provides a summary of the Trust's quarterly results, the distributions per Unit and the weighted average number of Units outstanding for the eight most recently completed quarters.

As at	2026	2025				2024		
	March 31	December 31	September 30	June 30	March 31	December 31	September 30	June 30
Total assets	\$ 916,384	\$ 942,819	\$ 909,046	\$ 967,257	\$ 962,045	\$ 984,867	\$ 884,079	\$ 874,067
Long-term debt	388,968	415,851	391,238	389,349	362,065	374,802	281,605	275,716
Three months ended	March 31	December 31	September 30	June 30	March 31	December 31	September 30	June 30
Total income	\$ 50,561	\$ 61,686	\$ 48,745	\$ 44,130	\$ 44,028	\$ 44,028	\$ 41,555	\$ 41,604
Total expenses	(42,154)	(53,995)	(58,845)	(42,783)	(45,780)	(54,520)	(43,247)	(45,149)
Gain (loss) on debt refinancing	(9,794)	789	—	(971)	—	—	—	2,176
Other loss	—	—	—	—	—	—	—	(764)
Termination fee	—	—	(48,000)	—	—	—	—	—
Income tax recovery (expense)	403	285	240	—	—	—	—	—
Net earnings (loss)	\$ (984)	\$ 8,765	\$ (57,860)	\$ 376	\$ (1,752)	\$ (10,492)	\$ (1,692)	\$ (2,133)
Net unrealized gain (loss) on derivative instruments	1,443	333	184	(1,076)	(80)	871	(1,632)	228
Comprehensive earnings (loss)	\$ 459	\$ 9,098	\$ (57,676)	\$ (700)	\$ (1,832)	\$ (9,621)	\$ (3,324)	\$ (1,905)
<b>Net earnings (loss) per Unit</b>								
Basic	\$ (0.02)	\$ 0.16	\$ (1.05)	\$ 0.01	\$ (0.03)	\$ 0.12	\$ (0.03)	\$ (0.04)
Diluted	\$ (0.02)	\$ 0.16	\$ (1.05)	\$ 0.01	\$ (0.03)	\$ 0.12	\$ (0.03)	\$ (0.04)
<b>Distributions per Unit<sup>(i)</sup></b>								
Cash	\$ 0.1100	\$ 0.1000	\$ 0.1000	\$ 0.1000	\$ 0.1000	\$ 0.0850	\$ 0.0850	\$ 0.0850
Unit <sup>(ii)</sup>	n/a	n/a	n/a	n/a	n/a	\$ 0.0237	n/a	n/a
<b>Weighted average number of Units</b>								
Basic	55,039,344	55,116,438	55,351,226	55,685,363	56,307,817	56,282,403	56,293,275	56,426,259
Diluted	55,039,344	55,311,470	55,351,226	55,685,363	56,307,817	56,678,956	56,293,275	56,426,259

(i) Represents distributions declared during the period.

(ii) On December 20, 2024, the board of trustees of the Trust declared a special Unit distribution of \$0.0237 per Unit, totaling \$1,334 to Unitholders of record as at December 31, 2024, which was issued on December 31, 2024. Immediately following the special Unit distribution, Units of the Trust were consolidated such that, after each consolidation, each Unitholder held the same number of Units as were held by the Unitholder immediately before the special Unit distribution.

## FINANCIAL REVIEW: NON-GAAP FINANCIAL MEASURES

The Trust reports certain non-GAAP financial measures, including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts, and Adjusted EBITDA. The Trust also reports certain non-GAAP ratios, including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized financial measures under IFRS Accounting Standards as issued by the IASB and might not be comparable to similar financial measures disclosed by other issuers.

### Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts

Total Cash Receipts refers to Total Cash Royalty Receipts plus cash receipts from all products. Total Cash Receipts includes cash receipts from interest as well as non-recurring cash receipts.

Total Cash Royalty Receipts refers to aggregate cash royalty receipts and milestone royalty receipts from our portfolio of royalty assets and forms part of Total Cash Receipts. Because of the lag between when we record royalty income and receive the corresponding cash payments on our royalties and milestones, we believe Total Cash Receipts and Total Cash Royalty Receipts are useful measures when evaluating our operations, as they represent actual cash generated in respect of all royalty assets held during a period. We also present Normalized Total Cash Receipts, which refers to Total Cash Receipts adjusted to remove cash receipts that are not expected to recur in the normal course of our operations. We believe that Normalized Total Cash Receipts will assist readers in evaluating the period-over-period performance of our royalty portfolio since Normalized Total Cash Receipts only includes cash receipts generated by royalties and other amounts payable pursuant to the terms of our royalty assets. There were no adjustments required to normalize cash receipts for the three months ended March 31, 2026 and 2025.

	Cash Receipts		\$ Change	% Change
	Three months ended March 31, 2026	Three months ended March 31, 2025		
<b>Royalty Assets</b>				
Casgevy	\$ 5,000	\$ 5,000	\$ —	— %
Ekterly	1,829	—	1,829	n/a
Empaveli/Syfovre	1,162	1,125	37	3 %
Eylea I	1,117	1,522	(405)	(27)%
Eylea II	238	331	(93)	(28)%
Omidria	8,684	7,994	690	9 %
Oracea	961	1,534	(573)	(37)%
Orserdu I <sup>(i)</sup>	16,600	8,510	8,090	95 %
Orserdu II	10,302	22,920	(12,618)	(55)%
Rydapt	793	1,159	(366)	(32)%
Spinraza	3,634	3,962	(328)	(8)%
Vonjo I	3,109	3,095	14	— %
Vonjo II	694	775	(81)	(10)%
Xenpozyme <sup>(ii)</sup>	—	—	—	n/a
Xolair	2,499	2,373	126	5 %
Zejula	1,017	949	68	7 %
Zytiga <sup>(iii)</sup>	—	—	—	n/a
Other Products <sup>(iv)</sup>	717	741	(24)	(3)%
<b>Total Cash Receipts, Normalized Cash Receipts and Cash Royalty Receipts</b>	<b>\$ 58,356</b>	<b>\$ 61,990</b>	<b>\$ (3,634)</b>	<b>(6)%</b>

(i) Cash receipts for Orserdu I for the three months ended March 31, 2026 include \$5,000 milestone royalty income related to the achievement of certain sales performance thresholds.

(ii) Xenpozyme royalty income is received on a semi-annual basis, with receipts expected in Q2 and Q4 each year.

(iii) Zytiga royalty income is received on a semi-annual basis, with receipts expected in Q2 and Q4 each year.

(iv) Other Products includes royalty income from certain other intangible royalty assets as well as intangible royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired. Comparative figures for royalty assets Natpara are included in Other Products.

### Q1 Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts

Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts during the three months ended March 31, 2026 decreased by \$3,634 or 6% compared to the same period in 2025. The decrease was driven primarily by Orserdu II, a decline in Eylea's sales due to biosimilar entries and market share pressure, and lower Oracea receipts due to competition and generics in the market. These declines were partially offset by a \$5,000 Orserdu I milestone receipt during the quarter resulting from the achievement of certain sales performance thresholds coupled with overall growth in Orserdu sales. The first quarter cash receipts also included royalties from the Ekterly royalty stream, which began generating cash receipts beginning in Q4 2025. Orserdu II cash royalty receipts during the three months ended March 31, 2025 included \$17,593 for reclamation of previous royalty deductions.

*Cash Receipt Reconciliation*

The reconciliation of Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts to the most directly comparable measures calculated in accordance with IFRS Accounting Standards as issued by the IASB is presented below. The Trust reconciles Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts to total income. Total income represents the sum of royalty income, change in fair value of financial royalty assets, net gain (loss) on marketable securities, net unrealized gains on derivative instruments, net unrealized gains on foreign exchange remeasurement and other interest income. Reconciling total income to Total Cash Receipts results in the subtraction of other interest income, net gain (loss) on marketable securities, net unrealized gains on derivative instruments, net unrealized gains on foreign exchange remeasurement, net change in royalties receivable, net change in financial royalty assets, non-cash royalty income and non-cash interest, and the addition of acquired royalties receivable.

When reconciling to Normalized Total Cash Receipts, we further subtract cash receipts not expected to recur, if any.

When reconciling to Total Cash Royalty Receipts, there is a corresponding subtraction to interest and other income on the loan receivable and an addition of non-cash interest and other income on the loan receivable and premiums for prepayment of loan receivable, since Total Cash Royalty Receipts is a measure of the Trust's cash royalty receipts from all products, excluding income from the Trust's debt instruments and cash receipts not expected to recur. For the purposes of complying with equal prominence requirements of applicable securities laws relating to non-GAAP financial measures, the Trust refers to total income when referring to Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Total income	\$ 50,561	\$ 44,028
[-] Other interest income	(223)	(298)
[-] Net (gain) loss on marketable securities	(168)	(1,535)
[-] Net unrealized gain on derivative instruments	(253)	—
[-] Net unrealized (gain) loss on foreign exchange remeasurement	(1,664)	—
[+] Royalties receivable, beginning of period	59,708	62,362
[-] Royalties receivable, end of period	(54,306)	(45,006)
[+] Financial royalty assets, beginning of period	57,276	57,527
[-] Financial royalty assets, end of period	(53,930)	(55,088)
[+] Non-cash royalty income <sup>(i)</sup>	1,355	—
<b>[=] Total Cash Receipts, Royalty Cash Receipts and Normalized Cash Receipts</b>	<b>\$ 58,356</b>	<b>\$ 61,990</b>

(i) Non-cash royalty income relates to Eylea I&II royalties that were deposited into an escrow account but had not yet been transferred to the operation account as of March 31, 2026.

## Adjusted EBITDA

We believe Adjusted EBITDA provides meaningful information about our operating cash flows as it eliminates the effects of other non-cash expenses and accruals and income and expenses not expected to recur that have been recorded on the interim condensed consolidated statements of net earnings (loss) and comprehensive earnings (loss). We refer to EBITDA when reconciling our net earnings (loss) and comprehensive earnings (loss) to Adjusted EBITDA, but we do not use EBITDA as a measure of our performance.

The reconciliation of Adjusted EBITDA to its most directly comparable measures calculated in accordance with IFRS Accounting Standards as issued by the IASB is presented below.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Comprehensive earnings (loss)	\$ 459	\$ (1,832)
[+] Amortization of intangible royalty assets	24,948	24,745
[+] Depreciation of fixed assets and other intangible assets <sup>(i)</sup>	88	—
[-] Income tax recovery	(403)	—
[-] Other interest income	(223)	(298)
[+] Interest expense	10,405	9,607
<b>[=] EBITDA</b>	<b>35,274</b>	<b>32,222</b>
[+] Royalties receivable, beginning of period	59,708	62,362
[-] Royalties receivable, end of period	(54,306)	(45,006)
[-] Performance fees payable, beginning of period	—	(1,665)
[+] Performance fees payable, end of period	—	2,198
[+] Financial royalty assets, beginning of period	57,276	57,527
[-] Financial royalty assets, end of period	(53,930)	(55,088)
[+] Unrealized (gain) loss on marketable securities <sup>(ii)</sup>	1,261	(1,535)
[+] Unit-based compensation	668	460
[+] Board of trustees' unit-based compensation <sup>(iii)</sup>	366	104
[+] (Gain) loss on debt refinancing	9,794	—
[-] Net (gain) loss on foreign exchange remeasurement	(1,664)	—
[-] Net unrealized gain (loss) on derivative instruments	(1,696)	80
<b>[=] Adjusted EBITDA</b>	<b>\$ 52,751</b>	<b>\$ 51,659</b>

(i) Included in general and administrative expenses are non-cash expenses related to the depreciation of fixed assets and amortization of other intangible assets.

(ii) Unrealized gain (loss) on marketable securities is related to the changes in fair value of the marketable securities prior to realizing gains/losses upon disposition.

(iii) Certain members of the board of trustees of the Trust elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan, as described on page 12 of this MD&A.

EBITDA during the three months ended March 31, 2026 was \$35,274, representing an increase of \$3,052 or 9% compared to the same period in 2025. The increase is primarily due to the Trust earning higher royalty income in three months ended March 31, 2026 by \$6,965 compared to the same period in 2025, coupled with lower expenses recorded during three months ended March 31, 2026.

Adjusted EBITDA during the three months ended March 31, 2026 was \$52,751, representing an increase of \$1,092 or 2% compared to the same period in 2025.

Impacting Adjusted EBITDA is the impact of certain non-recurring expenses. The table below details non-recurring expenses incurred during the three months ended March 31, 2026 and 2025.

	Three months ended March 31, 2026	Three months ended March 31, 2025
<b>Non-recurring expenses</b>		
Special committee fees <sup>(i)</sup>	\$ —	\$ 120
Professional fees related to improving governance <sup>(ii)</sup>	—	1,588
Professional fees related to internalization <sup>(ii)</sup>	—	2,199
Conversion option issuance costs <sup>(iii)</sup>	344	—
<b>Total non-recurring expenses</b>	<b>\$ 344</b>	<b>\$ 3,907</b>

(i) Included in board of trustee fees within other operating expenses were special committee costs related to the investigation and internalization.

(ii) Various professional fees were incurred by the Trust related to improving governance in the aftermath of the investigation of irregular expenses in 2024, and related to the internalization, as described on page 5 of this MD&A. These costs are included in professional fees within other operating expenses and are non-recurring by nature.

(iii) Various professional fees were incurred by the Trust related to the issuance of the conversion option on the Trust's debentures, as described on page 22 of this MD&A. These costs are included in professional fees within other operating expenses and are non-recurring by nature.

Adjusted EBITDA for the three months ended March 31, 2026 would have been \$53,095 (2025 – \$55,566) without non-recurring expenses related to the issuance of the debenture conversion option. Non-recurring expenses incurred in the prior year related to the internalization and the investigation, which were all resolved by December 31, 2025. Without the impact of these non-recurring expenses, Adjusted EBITDA is lower during the three months ended March 31, 2026 compared to the prior period primarily due to lower Royalty Cash Receipts.

### Adjusted EBITDA Margin

We believe that Adjusted EBITDA Margin is a useful supplemental measure to demonstrate the operating efficiency of our business on a cash basis.

The calculation of Adjusted EBITDA Margin is presented below.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Adjusted EBITDA	\$ 52,751	\$ 51,659
[+] Normalized Total Cash Receipts	\$ 58,356	61,990
<b>[=] Adjusted EBITDA Margin</b>	<b>90%</b>	<b>83%</b>

As described earlier, Adjusted EBITDA for the three months ended March 31, 2026 includes non-recurring expenses of \$344 (2025 – \$3,907). Without these non-recurring expenses, Adjusted EBITDA margin would have been 91% for the three months ended March 31, 2026 (2025 – 90%).

### Adjusted Cash Earnings per Unit

We believe that Adjusted Cash Earnings per Unit provides meaningful information about our performance as it provides a measure of the cash generated by our assets on a per Unit basis, excluding cash earnings that are not expected to recur.

The calculation of Adjusted Cash Earnings per Unit is presented below.

	Three months ended March 31, 2026	Three months ended March 31, 2025
Comprehensive earnings (loss)	\$ 459	\$ (1,832)
[+] Amortization of intangible royalty assets	24,948	24,745
[+] Depreciation of fixed assets and other intangible assets <sup>(i)</sup>	88	—
[+] Unrealized (gain) loss on marketable securities <sup>(ii)</sup>	1,261	(1,535)
[+] Unit-based compensation	668	460
[+] Board of trustees' unit-based compensation <sup>(iii)</sup>	366	104
[-] Change in fair value of financial royalty assets	(1,654)	(2,561)
[+] Cash receipts on financial royalty assets	5,000	5,000
[+] (Gain) Loss on debt refinancing	9,794	—
[-] Net (gain) loss on foreign exchange remeasurement	(1,664)	—
[-] Net unrealized (gain) loss on derivative instruments	(1,696)	80
<b>[=] Adjusted Cash Earnings (Loss)</b>	<b>\$ 37,570</b>	<b>\$ 24,461</b>
[+] Weighted average number of Units – basic	55,039,344	56,307,817
[=] Adjusted Cash Earnings (Loss) per Unit – basic	\$ 0.68	\$ 0.43
[+] Weighted average number of Units – diluted	55,039,344	56,307,817
[=] Adjusted Cash Earnings (Loss) per Unit – diluted	\$ 0.68	\$ 0.43

(i) Included in general and administrative expenses are non-cash expenses related to the depreciation of fixed assets and amortization of other intangible assets.

(ii) Unrealized gain (loss) on marketable securities is related to the changes in fair value of the marketable securities prior to realizing gains/losses upon disposition.

(iii) Certain members of the board of trustees of the Trust elected to be compensated fully or partially in DUs under the Trust's Omnibus Equity Incentive Plan, as described on page 12 of this MD&A.

Adjusted Cash Earnings (Loss) is \$37,570 for the three months ended March 31, 2026, an increase of \$13,109 compared to the same period in 2025. Basic and Diluted Adjusted Cash Earnings (Loss) for the three months ended March 31, 2026 is \$0.68 and \$0.68, respectively, compared to \$0.43 and \$0.43, respectively, for the same period in 2025. The increase in Adjusted Cash Earnings for the three months ended March 31, 2026 was primarily driven by higher royalty income of \$6,965, the inclusion of the realized gain on marketable securities of \$1,429, and lower expenses driven by continued realization of synergies due to internalization.

## FINANCIAL REVIEW: FINANCIAL POSITION

As at March 31, 2026, the Trust had consolidated total assets of \$916,384 (December 31, 2025 – \$942,819) and consolidated total liabilities of \$482,752 (December 31, 2025 – \$504,239). The following table presents the components of consolidated total assets and total liabilities as at March 31, 2026 and December 31, 2025, followed by a discussion of significant categories of assets and liabilities.

		As at March 31, 2026		As at December 31, 2025
<b>Assets</b>				
Cash and cash equivalents	\$	52,542	\$	42,432
Royalties receivable		54,306		59,708
Other current assets		1,517		983
<b>Current assets</b>		<b>108,365</b>		<b>103,123</b>
Intangible royalty assets, net of accumulated amortization and impairments		752,870		777,818
Financial royalty assets		53,930		57,276
Investment in marketable securities		—		3,311
Other non-current assets		1,219		1,291
<b>Non-current assets</b>		<b>808,019</b>		<b>839,696</b>
<b>Total assets</b>	<b>\$</b>	<b>916,384</b>	<b>\$</b>	<b>942,819</b>
<b>Liabilities</b>				
Accounts payable and accrued liabilities	\$	6,944	\$	6,240
Distributions payable to Unitholders		6,052		5,507
Current portion of credit facility		67,088		67,088
Current portion of unit-based compensation liability		1,739		1,704
Other current liabilities		4,888		5,810
<b>Current liabilities</b>		<b>86,711</b>		<b>86,349</b>
Long-term debt		388,968		415,851
Derivative instruments		6,417		1,486
Unit-based compensation liability		324		199
Other non-current liabilities		332		354
<b>Total liabilities</b>	<b>\$</b>	<b>482,752</b>	<b>\$</b>	<b>504,239</b>

### Intangible royalty assets

As at March 31, 2026, the net book value of our intangible royalty assets was \$752,870 (December 31, 2025 – \$777,818), net of accumulated amortization and impairments of \$412,334 (December 31, 2025 – \$387,386). During the three months ended March 31, 2026, the Trust recorded amortization of intangible royalty assets of \$24,948 (2025 – \$24,745).

During the year ended December 31, 2025, the Trust recorded additions to the cost of its intangible royalty assets of \$78,990 related to the veligrotug and elegrobart royalty transaction and the Ekterly one-time optional payment, as described on page 6 of this MD&A. The Trust also wrote off the cost, related accumulated amortization and accumulated impairments of \$41,730 related to the fully amortized intangible royalty assets as the royalty arrangements are no longer expected to generate material royalties. There was no change to the net book value of the intangible royalty assets as a result of these write-offs.

During the year ended December 31, 2025, the Trust recognized an impairment loss of \$23,365 related to the Vonjo II and Omidria royalty assets, as described on page 4 of this MD&A. The recoverable amount of Vonjo II and Omidria was based on a value-in-use calculation. The Trust determined the recoverable amount of the assets using a discounted cash flow model based on forecasted royalties and a discount rate of 8%. The net book value of the assets prior to recognizing an impairment exceeded the recoverable amounts and the difference of \$23,365 was recognized as an impairment loss. The impairment loss was recognized in the interim condensed consolidated statements of net earnings and comprehensive earnings.

### Financial royalty assets

As at March 31, 2026, the Trust had financial royalty assets of \$53,930 (December 31, 2025 – \$57,276), representing the fair value of the Casgevy royalty asset. During the three months ended March 31, 2026, the Trust had cash receipts of \$5,000, an increase in fair value due to the passage of time of \$1,868, and a decrease in fair value due to changes in the risk-free rate of \$214.

### Distributions payable to Unitholders

As at March 31, 2026, the Trust had distributions payable of \$6,052, representing a quarterly cash distribution declared on March 3, 2026 to Unitholders of record as at March 31, 2026, which was paid on April 20, 2026.

As at December 31, 2025, the Trust had distributions payable of \$5,507, representing a quarterly cash distribution declared on November 5, 2025 to Unitholders of record as at December 31, 2025, which was paid on January 20, 2026.

The Trust pays a quarterly distribution in accordance with its distribution policy, as described in note 7 to the consolidated financial statements.

### Long-term debt

The Trust's long-term debt is composed of its i) long-term portion of credit facility; ii) preferred securities; iii) convertible debentures; and iv) senior notes. The carrying amount of the Trust's long-term debt as at March 31, 2026 and December 31, 2025 is presented below.

		As at March 31, 2026	As at December 31, 2025
Credit facility – long-term	\$	50,181	\$ 313,953
Preferred securities		31,219	108,862
Debentures		69,276	—
Senior notes		250,000	—
Deferred transaction costs, net of amortization		(11,708)	(6,964)
<b>Total</b>	<b>\$</b>	<b>388,968</b>	<b>\$ 415,851</b>

### Credit facility

On October 22, 2021, the Trust entered into a credit agreement for credit facilities composed of a \$175,000 senior secured revolving acquisition credit facility (the "**acquisition credit facility**") and a \$25,000 senior secured revolving working capital credit facility (the "**working capital credit facility**"), the proceeds from which were used for general business purposes and to finance transactions. On April 20, 2022, the Trust entered into an amended and restated credit agreement (the "**credit agreement**"), as further amended and restated from time to time, that added a new tranche to the credit facilities consisting of a \$150,000 delayed draw term loan (the "**term credit facility**"), collectively, the "**credit facility**") which can be drawn against to fund future transactions.

On May 12, 2025, the Trust revised its credit agreement to reallocate \$25,000 of the acquisition credit facility to the working capital credit facility, increasing it to \$50,000. The credit available for investment remains unchanged as the working capital credit facility can be used for investment purposes. Furthermore, the interest rate on the credit agreement was revised to SOFR plus (i) a margin which may vary from 1.75% to 2.50% based on the Trust's leverage ratio; and (ii) a margin of 0.10%. All other material terms of the credit agreement remain unchanged.

On October 3, 2025, the Trust further amended its credit agreement to, among other things, convert and merge the term credit facility into the acquisition credit facility. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250. This increased the total credit available under the acquisition credit facility to \$570,000. The Trust also extended the maturity date of the amended credit agreement by two years to October 3, 2029, which may be extended by one-year increments subject to lender approval. Certain other terms were also adjusted to provide the Trust with greater flexibility. All other material terms of the credit agreement remain unchanged.

On February 24, 2026, the Trust amended its credit agreement to permit the Senior Notes, as described on page 22 of this MD&A. The amendment also included having the Senior Notes rank *pari passu* with the credit agreement and to be secured by the same collateral.

Interest payments on the outstanding loan are due on a quarterly basis and mandatory principal repayments totaling 3.75% of a predetermined reference amount are due on a quarterly basis for the acquisition credit facility. Principal repayments on the working capital credit facility are due on maturity. Principal repayments do not result in a corresponding decrease in the borrowing capacity under the acquisition credit facility and working capital credit facility.

The carrying amount of the Trust's credit facility is presented below.

	As at March 31, 2026			As at December 31, 2025
	Total Available Credit	Remaining Available Credit	Balance Outstanding	Balance Outstanding
Acquisition credit facility	\$ 570,000	\$ 476,731	\$ 93,269	\$ 332,041
Working capital credit facility	50,000	26,000	24,000	49,000
	\$ 620,000	\$ 502,731	\$ 117,269	\$ 381,041
Deferred transaction costs, net of amortization	n/a	n/a	(4,791)	(4,977)
<b>Total</b>	<b>\$ 620,000</b>	<b>\$ 502,731</b>	<b>\$ 112,478</b>	<b>\$ 376,064</b>
Current portion of credit facility			\$ 67,088	\$ 67,088
Long-term portion of credit facility, net of unamortized transaction costs			45,390	308,976
<b>Total</b>			<b>\$ 112,478</b>	<b>\$ 376,064</b>

During the three months ended March 31, 2026, the Trust did not make any drawings on its credit facility. The decrease in the carrying amount of the credit facility is attributed to the principal repayments made during the quarter of \$263,772 (2025 – \$14,222), including a principal repayment of \$247,000 (2025 – nil) in connection with the issuance of the Senior Notes, as described on page 22 of this MD&A.

The following table presents expected principal repayments to be made until the maturity of the credit facility as at March 31, 2026.

	Total
Remainder of: 2026	\$ 50,316
2027	42,953
2028	—
2029	24,000
	<b>\$ 117,269</b>

The Trust is subject to certain financial as well as customary non-financial covenants under the credit agreement. Certain compliance requirements have also been revised as part of the amendments to the credit agreement. Substantially all of the assets of the Trust are pledged as collateral under the credit agreement. As at March 31, 2026, the Trust was in compliance with all covenant requirements under the credit agreement.

#### Interest Rate Swap

On August 31, 2023, the Trust entered into an interest rate swap agreement to fix the interest rate on a notional amount of \$100,000 of the credit facility.

On June 10, 2025, to reflect changes resulting from amendments to the amended credit agreement, the Trust extended the maturity on its original interest rate swap to November 1, 2027. On June 10, 2025, the Trust also entered into a second interest rate swap with equivalent terms for an additional notional amount of \$50,000. Under the agreements, the Trust pays a fixed rate and in exchange receives a SOFR interest rate, offsetting the floating component on a portion of the credit facility.

On December 1, 2025, as a result of the October 3, 2025 amendment to the credit agreement, the Trust further modified its interest rate swaps. The maturity dates for both swaps were extended to September 28, 2029. The second aforementioned interest swap was combined with the amended interest rate swap into a single \$150,000 notional interest rate swap.

During the three months ended March 31, 2026, the Trust recorded an increase in interest due to the interest rate swaps of \$307 (2025 – increase of \$75).

#### Preferred Securities

On April 23, 2024, the Trust completed a refinancing of the Series A Preferred Securities, the Series B Preferred Securities (collectively, the "2023 Preferred Securities"), and the Warrants issued in 2023 (the "2023 Warrants"). As a result of the refinancing, holders of the 2023 Preferred Securities received \$135,202 principal amount of the 2024 Preferred Securities and 1,749,996 new Warrants (the "2024 Warrants"). The 2023 Preferred Securities were canceled and the 2023 Warrants were canceled upon completion of the refinancing.

The 2024 Preferred Securities are unsecured, subordinated debt securities of the Trust maturing on April 23, 2074. The 2024 Preferred Securities will mature on April 23, 2074. The 2024 Preferred Securities initially pay cash interest at a rate of 7.50% per annum on the principal amount, payable semi-annually on April 30 and October 31 of each year. The 2024 Preferred Securities are not redeemable by the Trust prior to April 30, 2029, except in the event of a change in control of the Trust. The interest rate on the 2024 Preferred Securities will increase to 10% per annum if any of the 2024 Preferred Securities are outstanding on April 30, 2029, and will be subject to an annual increase of 1.5% per annum if any of the 2024 Preferred Securities remain outstanding on each one year anniversary of such date, up to a specified cap.

On June 18, 2025, the Trust entered into an agreement with a holder of the 2024 Preferred Securities to partially purchase and cancel \$10,000 in face value of the 2024 Preferred Securities for \$9,500. The Trust paid outstanding accrued interest on the \$10,000 face value up to and including June 18, 2025, the date of the transaction.

On February 10, 2026, the Trust entered into another agreement with a holder of the 2024 Preferred Securities to further partially purchase and cancel \$9,924 in face value of the 2024 Preferred Securities for \$9,825. The Trust paid outstanding accrued interest on the \$9,924 face value up to February 10, 2026, the date of the transaction. During the three months ended March 31, 2026, the Trust recorded a loss of \$1,162 related to the change in the gross carrying amount of the partial cancellation (2025 – nil), which is included in gain (loss) on debt refinancing in the interim condensed consolidated statements of net earnings and comprehensive earnings.

On March 20, 2026, the Trust issued C\$108,723 aggregate principal amount of convertible unsecured subordinated debentures (the “**debentures**”) to the holders of the 2024 Preferred Securities. The purchase price for the debentures was exclusively satisfied through the exchange of \$79,698 in principal amount of the 2024 Preferred Securities. No cash consideration was paid by the holders of the 2024 Preferred Securities. The difference between the carrying amount of the 2024 Preferred Securities, excluding the related unamortized deferred transaction costs, and the fair value of the debentures as at March 20, 2026, the date of the transaction, was \$7,380, which was recognized as a loss on debt refinancing in the interim condensed consolidated statements of net earnings and comprehensive earnings. As at March 20, 2026, an aggregate principal amount of \$35,580 of the 2024 Preferred Securities remain issued and outstanding, the terms of which remain unchanged. Unamortized deferred transaction costs related to the extinguished portion of the 2024 Preferred Securities of \$1,252 are also recognized as a loss on debt refinancing.

The carrying amount of the preferred securities is presented below.

		As at March 31, 2026		As at December 31, 2025
Series C Preferred Securities	\$	31,219	\$	108,862
Deferred transaction costs, net of amortization		(554)		(1,987)
<b>Total</b>	<b>\$</b>	<b>30,665</b>	<b>\$</b>	<b>106,875</b>

#### Convertible Debentures

On March 20, 2026, the Trust issued debentures to the holders of the 2024 Preferred Securities, as described above. The debentures are denominated in Canadian dollars and bear interest at a rate of 5.75% per annum on the principal amount, payable semi-annually on February 28 and August 31 of each year and mature on February 28, 2031. The debentures are convertible at the holder's option into Units of the Trust at any time prior to the maturity date, at a conversion price of C\$21.99 per Unit (“**conversion option**”). The debentures are redeemable at the Trust's option between February 28, 2029 to February 27, 2030, subject to conditions. On and after February 28, 2030, the debentures are redeemable at the Trust's option at par plus accrued and unpaid interest. The Trust also has the option to settle the debentures upon redemption or at maturity by issuing and delivering the Trust's Units at 95% of a prescribed market price.

The Trust initially recognized the debentures using a discount rate of 7.5%, which is indicative of the fair market value of the debentures at the time of issuance. The carrying amount of the debentures will be accreted to its par value up until its maturity date. Deferred transaction costs of \$3,740 attributable to the issuance of the debentures were initially recognized and will be amortized using the effective interest rate method over the same period as the debentures accretion period.

The carrying amount of the debentures is presented below.

		As at March 31, 2026		As at December 31, 2025
Debentures	\$	69,276	\$	—
Deferred transaction costs, net of amortization		(3,717)		—
<b>Total</b>	<b>\$</b>	<b>65,559</b>	<b>\$</b>	<b>—</b>

The Trust determined that the conversion option is classified as an embedded derivative liability and is separately recognized from the carrying amount of the debentures. Transaction costs of \$344 attributable to the issuance of the conversion option were included in other operating expenses. The exercise price represents a 30% premium to the volume weighted average price of the Trust's Units from February 25, 2026 to February 27, 2026. The fair market value of the conversion option was initially recognized as \$6,497 upon issuance using the Black-Scholes valuation model. The assumptions used to determine the fair value of the conversion option include: (i) exercise price of C\$21.99; (ii) average risk-free interest rate of 2.5%; (iii) expected maturity date of February 28, 2031; (iv) average expected volatility of 25%; and (v) expected distribution yield of 3.23%.

#### Senior Notes

On March 24, 2026, the Trust completed a private placement of \$250,000 Senior Notes, consisting of a Series A tranche with \$106,000 in aggregate principal amount maturing on March 24, 2031 and a Series B tranche with \$144,000 in aggregate principal amount maturing on March 24, 2033. The Series A Senior Notes bear interest at a rate of 5.35% per annum and the Series B Senior Notes bear interest at a rate of 5.65% per annum, both payable semi-annually on June 30 and December 31 of each year. The Senior Notes are secured on a first lien basis, rank *pari passu* with the credit agreement and are secured by the same assets of the Trust that are pledged under the credit agreement. Total proceeds net of transaction costs of \$247,000 were used to repay the Trust's credit facility. Deferred transaction costs of \$2,653 were recognized and amortized using the effective interest rate method up to the maturity date.

The carrying amount of the Senior Notes is presented below.

		As at March 31, 2026		As at December 31, 2025
Series A Senior Notes	\$	106,000	\$	—
Series B Senior Notes		144,000		—
Deferred transaction costs, net of amortization		(2,646)		—
<b>Total</b>	<b>\$</b>	<b>247,354</b>	<b>\$</b>	<b>—</b>

## FINANCIAL REVIEW: CASH FLOWS

The Trust generated the following cash flows during the three months ended March 31, 2026 and 2025.

		Three months ended March 31, 2026		Three months ended March 31, 2025
Cash and cash equivalents – beginning of period	\$	42,432	\$	36,502
Cash provided by operating activities		47,107		48,825
Cash used in financing activities		(45,476)		(24,671)
Cash provided by (used in) investing activities		8,479		(5,000)
Change in cash and cash equivalents		10,110		19,154
Cash and cash equivalents – end of period	\$	52,542	\$	55,656

During the three months ended March 31, 2026, the Trust generated cash flows provided by operating activities of \$47,107, \$1,718 lower compared to the same period in 2025. The decrease was primarily driven by lower Cash Royalty Receipts compared to 2025, partially offset by lower cash expenses incurred during the three months ended March 31, 2026.

For the three months ended March 31, 2026, the Trust used cash flows of \$45,476 from financing activities, a \$20,805 increase in cash used compared to the same period in 2025. The increase is primarily attributable to \$9,825 paid on the partial cancellation of the 2024 Preferred Securities and \$6,955 paid on the issuance of the Trust's Senior Notes and debentures during the three months ended March 31, 2026, both of which were not incurred during 2025. The Trust also paid higher interest and higher distributions to Unitholders during the three months ended March 31, 2026 compared to the same period in 2025. During the three months ended March 31, 2026, the Trust received proceeds of \$250,000 related to the issuance of the Senior Notes, then used available cash of \$263,772 to repay its credit facility, repurchased and cancelled Units under its NCIB program for \$859 and paid related excise tax of \$245.

For the three months ended March 31, 2026, the Trust generated cash flows of \$8,479 from investing activities, \$13,479 higher compared to the same period in 2025. The increase was primarily attributed to proceeds of \$3,479 from the sale of marketable securities, which did not occur in 2025. The Trust also did not complete royalty transactions during the three months ended March 31, 2026, which reduced cash usage of \$10,000 compared to the same period in 2025.

## EQUITY

### Authorized equity

The Trust's authorized equity capital consists of (i) an unlimited number of Units; and (ii) an unlimited number of Preferred Units, issuable in series. Issued and outstanding Units may be subdivided or consolidated from time to time by the Trust without notice to, or the approval of, the Unitholders.

### Units

Each Unit represents a proportionate undivided beneficial ownership interest in the Trust, which entitles the holder to one vote, participation in distributions made by the Trust on a pro rata basis and, in the event of the termination or winding-up of the Trust, in the pro rata share of its net assets remaining after the satisfaction of all its liabilities. Units are discussed in further detail in note 7 to the consolidated financial statements. As at March 31, 2026, 55,017,221 (December 31, 2025 – 55,073,836) Units were outstanding at a cost of \$549,590 (December 31, 2025 – \$550,235).

The following table outlines the changes in the number of Units outstanding from December 31, 2024 to March 31, 2026.

	Units	Weighted Average Cost per Unit	Total Cost
<b>Balance – December 31, 2024</b>	<b>56,304,425</b>	<b>n/a</b>	<b>\$ 562,583</b>
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	6,495	\$ 8.36	\$ 54
<b>Balance – March 31, 2025</b>	<b>56,310,920</b>	<b>n/a</b>	<b>\$ 562,637</b>
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	194,406	\$ 9.84	\$ 1,912
Units issued on the settlement of vested Deferred Units	17,759	9.10	162
Repurchase and cancellation of Units – NCIB	(1,449,249)	9.82	(14,231)
Excise tax on share repurchases	n/a	n/a	(245)
<b>Balance – December 31, 2025</b>	<b>55,073,836</b>	<b>n/a</b>	<b>\$ 550,235</b>
Issuance of Units:			
Units issued on the settlement of vested Restricted Units	19,323	\$ 11.69	\$ 226
Repurchase and cancellation of Units – NCIB	(75,938)	\$ 11.31	\$ (859)
Excise tax on share repurchases	n/a	n/a	(12)
<b>Balance – March 31, 2026</b>	<b>55,017,221</b>	<b>n/a</b>	<b>\$ 549,590</b>

### Settlement of vested Restricted Units

The following table outlines the Units issued upon settlement of vested RUs during the three months ended March 31, 2026, the three months ended March 31, 2025 and the period from April 1, 2025 to December 31, 2025.

	Units Issued on Settlement of Restricted Units		
	Three months ended March 31, 2026	Three months ended March 31, 2025	Nine months ended December 31, 2025
Restricted Units Grant Date:			
June 10, 2022	—	—	6,878
September 10, 2022	—	—	11,613
November 22, 2022	—	—	14,033
August 17, 2023	—	—	2,907
October 25, 2023	—	—	28,770
December 21, 2023	—	—	2,547
January 10, 2024	—	—	75,410
May 1, 2024	—	—	2,909
May 31, 2024	—	—	12,851
August 13, 2024	6,740	6,495	20,118
July 1, 2025	11,539	—	13,829
September 4, 2025	—	—	1,506
November 10, 2025	1,044	—	1,035
<b>Total</b>	<b>19,323</b>	<b>6,495</b>	<b>194,406</b>

The increase in the number of Units issued upon the settlement of vested RUs during the three months ended March 31, 2026 compared to the same period in 2025 is due to a higher number of RUs vesting and settling during the current quarter.

### Normal course issuer bid

From time to time, the market price of the Units of the Trust may not adequately reflect the value of the underlying assets of the Trust, and management wishes to take advantage of the market trading prices of its Units in those instances.

On May 9, 2025, the Trust was granted approval for the May 2025 NCIB by the TSX. In connection with the May 2025 NCIB, the Trust established an AUPP whereby Units of the Trust may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

During the three months ended March 31, 2026, the Trust acquired and canceled 75,938 Units at an average price of \$11.31, totaling \$859. As at March 31, 2026, in aggregate, the Trust has acquired and canceled 4,688,696 Units at an average price per Unit of \$7.15, totaling \$33,517 under the NCIB Plans.

As a SIFT trust, the Trust is subject to a 2% excise tax on the excess of the fair market value of equity repurchases over equity issuances, unless such repurchases are below the exemption threshold of C\$1,000. For the three months ended March 31, 2026, the Trust recorded an excise tax of \$12 related to repurchases under the May 2025 NCIB program.

As at March 31, 2026, the Trust recorded an other current liability of \$2,000 representing the maximum amount that would be required to settle the AUPP in effect on March 31, 2026, with a corresponding decrease in other equity. The actual number of Units repurchased under the AUPP may be less than the estimate as at March 31, 2026, resulting in a decrease in other current liabilities and an increase in other equity.

Subsequent to March 31, 2026, the Trust was granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,060,594 Units of the Trust for cancellation between May 20, 2026 and May 19, 2027. In connection with this approval, the Trust established an AUPP whereby Units of the Trust may be repurchased between May 20, 2026 and May 19, 2027 at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

In the subsequent period from April 1, 2026 to May 14, 2026, the Trust acquired an additional 60,052 Units under the May 2025 NCIB plan at an average price of \$11.65, totaling \$700 under the AUPP.

### Warrants

On April 23, 2024 the Trust completed a refinancing of the 2023 Preferred Securities and the 2023 Warrants, as described on page 21 of this MD&A. As a result of the refinancing, the 2023 Warrants were redeemed for \$20,441 and 1,749,996 2024 Warrants were issued. Each 2024 Warrant entitles the holder thereof to acquire one Unit of the Trust for an exercise price of \$15.00 at any time until the expiry of the 2024 Warrants on April 23, 2029.

The fair value of the 2024 Warrants was estimated at \$4,322 on issuance date using the Black-Scholes valuation model. The assumptions used to determine the fair value of the 2024 Warrants include: (i) an exercise price of \$15.00; (ii) an average risk-free interest rate of 4.38%; (iii) a five-year term; (iv) an average expected volatility of 30.5%, estimated based on market data; and (v) an expected distribution yield of 3.35%.

As at March 31, 2026, the net value of the 2024 Warrants recognized in other equity reserves was \$4,106 (December 31, 2025 – \$4,106).

### Distributions

The Trust pays quarterly distributions in accordance with its distribution policy, which is described in the Trust's most recent annual information form. The following table presents cash and Unit distributions made by the Trust during the three months ended March 31, 2026 and year ended December 31, 2025.

	Record Date	Payment Date	Distribution per Unit	Total Distribution
<b>2026</b>				
Q1 2026 – Quarterly cash distribution	March 31, 2026	April 20, 2026	\$ 0.1100	\$ 6,052
<b>Total</b>			<b>\$ 0.1100</b>	<b>\$ 6,052</b>
<b>2025</b>				
Q1 2025 – Quarterly cash distribution	March 31, 2025	April 17, 2025	\$ 0.1000	\$ 5,631
Q2 2025 – Quarterly cash distribution	June 30, 2025	July 18, 2025	0.1000	5,550
Q3 2025 – Quarterly cash distribution	September 30, 2025	October 20, 2025	0.1000	5,515
Q4 2025 – Quarterly cash distribution	December 31, 2025	January 20, 2026	0.1000	5,507
<b>Total</b>			<b>\$ 0.4000</b>	<b>\$ 22,203</b>

During the three months ended March 31, 2026, the board of trustees of the Trust declared cash distributions totaling \$6,052 (2025 – \$5,631).

Subsequent to March 31, 2026, the board of trustees of the Trust declared a quarterly cash distribution of \$0.1100 per Unit to Unitholders of record as at June 30, 2026 and payable on July 20, 2026.

## LIQUIDITY AND CAPITAL RESOURCES

As at March 31, 2026, the Trust's capital was \$1,021,676 (December 31, 2025 – \$1,044,460) and consisted of its Unitholders' capital of \$549,590 (December 31, 2025 – \$550,235), current portion and long-term debts of \$467,764 (December 31, 2025 – \$489,903) and 2024 Warrants of \$4,322 (December 31, 2025 – \$4,322). All capital items are shown prior to the deduction of deferred transaction costs, net of amortization.

The Trust's objectives in managing capital are to:

- Build long-term value for its Unitholders;
- Maintain optimal liquidity for pursuing acquisitions, meeting its obligations and making distributions to Unitholders;
- Achieve reasonable return on capital and control the risk and exposure associated with capital investments; and
- Maintain an optimal capital structure and reduce the cost of capital.

The Trust has access to a number of capital sources, including: (i) cash on hand; (ii) internally generated cash flows; (iii) debt and other financing; (iv) the issuance of Trust Units to royalty sellers; and (v) future public equity issuances.

The Trust's primary ongoing source of liquidity is cash provided by operating activities. During the three months ended March 31, 2026, the Trust generated \$47,107 (2025 – \$48,825) of cash provided by operating activities.

On June 18, 2025, the Trust partially purchased and canceled \$10,000 in face value of the 2024 Preferred Securities for \$9,500, as described on page 21 of this MD&A.

On October 3, 2025, the Trust revised its amended credit agreement to convert and merge the term credit facility into the acquisition credit facility, as described on page 20 of this MD&A. The total credit available under the acquisition credit facility increased by \$70,000 and the outstanding amount under the acquisition credit facility increased by an amount corresponding to the outstanding amount under the term credit facility as at October 3, 2025, which was \$63,250.

On February 10, 2026, the Trust further partially purchased and canceled \$9,924 in face value of the 2024 Preferred Securities for \$9,825, as described on page 21 of this MD&A.

On March 20, 2026, the Trust issued C\$108,723 aggregate principal amount of debentures to the 2024 Preferred Securities holders in exchange for the cancellation of \$79,698 in principal amount of 2024 Preferred Securities, as described on page 21 of this MD&A. Upon closing, an aggregate principal amount of \$35,580 of the 2024 Preferred Securities will remain issued and outstanding.

On March 24, 2026, the Trust completed a private placement of \$250,000 of Senior Notes, consisting of two tranches, as described on page 22 of this MD&A. The Trust used the net proceeds of the Senior Notes to repay a portion of its acquisition and working capital credit facilities.

The Trust believes its existing capital resources and cash provided by operating activities will continue to allow the Trust to meet its operating and working capital requirements, and to meet externally imposed capital requirements and obligations, including the scheduled repayments of its credit facility for the foreseeable future.

As at March 31, 2026, the Trust was in compliance with all externally imposed capital requirements.

## OFF-BALANCE SHEET OBLIGATIONS AND COMMITMENTS

On November 25, 2022, the Trust bought royalties on the sales of Xenpозyme. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$26,000 in the event that cumulative royalties received by the Trust on Xenpозyme sales exceed certain thresholds within a predefined period of time.

On April 3, 2023, the Trust bought an additional stream on Empaveli/Syfovre. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to an additional payment of \$4,000 in the event that Empaveli/Syfovre sales exceed certain thresholds within a predefined period of time.

On August 16, 2023, the Trust entered into a pledge agreement with the Mayo Clinic. In accordance with the terms of the agreement, the Trust intends to contribute \$5,000 in total (\$1,000 annually, payable in quarterly installments) to the Mayo Clinic to directly support and further the Center for Regenerative Biotherapeutics. To date, the Trust has paid a total of \$2,750.

On February 1, 2024, the Trust amended the existing Omidria royalty agreement. In accordance with the terms of the amended royalty agreement, the royalty seller may be entitled to an additional payment of up to \$27,500 in potential sales-based milestone payments.

On June 28, 2024, the Trust bought an additional royalty stream on Xenpозyme. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$32,500 in potential performance-based milestone payments.

On November 4, 2024, the Trust bought a royalty interest in Ekterly. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to receive up to \$79,000, composed of up to \$57,000 in sales-based milestones and \$22,000 in a one-time optional payment. On July 7, 2025, after receiving FDA approval of Ekterly, the royalty seller elected to receive the one-time optional payment of \$22,000, increasing the royalty rate entitled to by the Trust. After exercising the one-time optional payment, the royalty seller's potential one-time sales-based milestone payment increased to \$57,000 from \$50,000, contingent on annual worldwide net sales of Ekterly meeting or exceeding \$550,000 before January 1, 2031.

On October 17, 2025, the Trust completed the veligotug and elegrobart transaction, as described on page 6 of this MD&A. In accordance with the terms of the royalty agreement, the royalty seller may be entitled to additional consideration of up to \$245,000 subject to the achievement of certain milestones. As of March 31, 2026, certain clinical milestone achievements were not met, reducing the Trust's potential milestone obligation to \$205,000, of which \$75,000 is related to a near-term regulatory milestone payment.

The Trust did not have any other off-balance sheet obligations, commitments or guarantees at March 31, 2026.

## CONTINGENT LIABILITY

On or about September 19, 2024, a statement of claim was issued on behalf of Andrea Reid, seeking leave to institute a securities class proceeding before the Ontario Superior Court of Justice against Persis Capital Inc. (formerly DRI Capital Inc.), DRI Healthcare Trust, Behzad Khosrowshahi, former CEO of Persis Capital Inc. and the Trust and Chris Anastasopoulos, former CFO of Persis Capital Inc. and the Trust, on behalf of a class of investors who acquired Units of the Trust between February 11, 2021 to August 6, 2024 (and held such Units until August 6, 2024).

In connection with the internalization described on page 5 of this MD&A, the former external manager agreed to fully indemnify the Trust against the damages arising from the legal proceeding described above. No amounts have been accrued as of March 31, 2026.

During the three months ended March 31, 2026, a settlement of C\$8,000 was reached among the parties in the legal proceeding described above. The Trust is not responsible to pay or contribute any monies towards the settlement amount.

## RELATED-PARTY TRANSACTIONS

Persis Capital Inc. (formerly DRI Capital Inc.) served as the external manager of the Trust until June 30, 2025. Management fees and performance fees were payable by the Trust pursuant to the management agreement prior to the internalization. On July 1, 2025, the Trust completed the internalization of its management function and terminated the management agreement with the former external manager, as described on page 5 of this MD&A, and as a result, management and performance fees are no longer payable by the Trust. The following related-party transactions occurred during the three months ended March 31, 2026 and 2025.

### Management fees

Prior to the termination of the management agreement, the Trust was required to pay quarterly management fees to the former external manager or its affiliates equal to 6.50% of total cash receipts for such quarter and 0.25% of the fair value of security investments and related derivative financial instruments as of the end of such quarter, as described in note 3(m) to the Trust's 2025 consolidated financial statements. As a result of the internalization, no management fees were incurred or paid during the three months ended March 31, 2026. During the three months ended March 31, 2025, the Trust recorded management fees to the former external manager of \$4,076.

### Performance fees

The former external manager was entitled to performance fees determined on a portfolio-by-portfolio basis pursuant to the terms of a management agreement, as described in note 3(n) to the Trust's 2025 consolidated financial statements. As a result of the internalization, no performance fees were incurred or paid during the three months ended March 31, 2026. The Trust recorded performance fees of \$533 during the three months ended March 31, 2025, as the conditions for performance fees were met primarily due to the cash receipt of Casgevy in the first quarter of 2025.

### Key management compensation

During the three months ended March 31, 2026 and 2025, the Trust issued compensation to members of the board of trustees of the Trust, as described on page 11 of this MD&A, and to certain officers of the Trust, as detailed below.

		Three months ended March 31, 2026	Three months ended March 31, 2025
Cash compensation and short-term benefits <sup>(i)</sup>	\$	1,596	\$ 369
Unit-based compensation		589	168
<b>Total</b>	<b>\$</b>	<b>2,185</b>	<b>\$ 537</b>

(i) Prior period figures have been adjusted to conform with the current period's classification.

During the three months ended March 31, 2026, the Trust recorded total cash compensation and short-term benefits expense of \$1,596 (2025 – \$369) related to compensation paid to certain officers of the Trust, including salaries, bonuses and benefits.

During the three months ended March 31, 2026, the Trust recorded unit-based compensation expense of \$589 (2025 – \$168) related to the RU grants and the accretion of the related distribution equivalent Units.

The following table details the RUs granted to certain officers of the Trust during the three months ended March 31, 2026.

Restricted Units Grant Date:	Total Units January 1, 2025	Units Granted	Distribution Equivalent Units Granted <sup>(i)</sup>	Vesting of Restricted Units	Total Units March 31, 2026
August 13, 2024 <sup>(ii)</sup>	44,104	—	264	(14,701)	29,667
July 1, 2025 <sup>(iii)</sup>	75,806	—	454	(25,268)	50,992
July 1, 2025 <sup>(iv)</sup>	101,073	—	908	—	101,981
September 4, 2025 <sup>(v)</sup>	13,365	—	120	—	13,485
October 15, 2025 <sup>(iv)</sup>	17,308	—	155	—	17,463
November 10, 2025 <sup>(vi)</sup>	6,746	—	40	(2,248)	4,538
March 31, 2026 <sup>(vii)</sup>	—	5,271	47	—	5,318
<b>Balance</b>	<b>258,402</b>	<b>5,271</b>	<b>1,988</b>	<b>(42,217)</b>	<b>223,444</b>

(i) All RUs are credited with distribution equivalents in the form of additional RUs on each distribution payment date in respect of which normal distributions are paid on the Trust's Units. Such distribution equivalents are subject to the same vesting conditions as the instruments to which they relate.

(ii) Vesting equally on a quarterly basis beginning November 13, 2024 until August 13, 2026.

(iii) Vesting equally on a quarterly basis beginning October 1, 2025 until July 1, 2026.

(iv) Vesting equally over three years on each anniversary date.

(v) Vesting equally on April 1, 2026, April 1, 2027 and April 1, 2028.

(vi) Vesting equally on a quarterly basis beginning November 13, 2025 until August 13, 2026.

(vii) Vesting on March 31, 2029.

The following table outlines the Units issued upon settlement of vested RUs to certain officers of the Trust during the three months ended March 31, 2026.

Restricted Units Grant Date:	Units Issued on Settlement of Restricted Units Three months ended March 31, 2026
August 13, 2024	6,740
July 1, 2025	11,539
November 10, 2025	1,044
<b>Total</b>	<b>19,323</b>

## CHANGES IN ACCOUNTING POLICIES

The Trust's accounting policies are discussed in detail in note 3 to the Trust's 2025 consolidated financial statements. There were no changes to the accounting policies during the three months ended March 31, 2026.

## CRITICAL ACCOUNTING ESTIMATES

In the preparation of this MD&A, the Trust has used consistent judgment and estimates as described in note 4 to the Trust's 2025 consolidated financial statements.

## SUBSEQUENT EVENTS

### NCIB repurchases

From the period of April 1, 2026 to May 14, 2026, the Trust acquired 60,052 Units under the May 2025 NCIB plan at an average price of \$11.65, totaling \$700 under the AUPP, as described on page 24 of this MD&A.

On May 12, 2026, the Trust was granted approval by the TSX to acquire, from time to time, if considered advisable, up to 3,060,594 Units of the Trust for cancellation between May 20, 2026 and May 19, 2027. In connection with this approval, the Trust established an AUPP whereby Units of the Trust may be repurchased between May 20, 2026 and May 19, 2027 at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP.

### 2026 second quarter distribution declared

On May 14, 2026, the board of trustees of the Trust declared a quarterly distribution of \$0.1100 per Unit to Unitholders of record as at June 30, 2026 and payable on July 20, 2026.